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Introduction  
 
Early Detection and Screening for Childhood Deafness 
Deafness is considered in a child when hearing loss is severe to profound 
(average thresholds >70-90 dB) such that linguistic information cannot be 
processed accordingly. Congenital hearing loss remains as one of the most 
common of congenital disorders in children affecting 1.5- 6.9 per 1000 live births 
(Parving 1999; Parving and Haunch 2001). In more than 50% of cases the cause 
is genetic mostly due to GJB2 or GJB6 mutations (Morton 1991; Cohen and Gorlin 
1995; Norris et al. 2006) but may be lower from 19%-30% depending perhaps on 
the severity of hearing loss in the population studied (Chinetti et al. 2010; Roux et 
al. 2004; Cama et al. 2009). Of the genetically caused or hereditary hearing loss 
approximately 70% are classified to be non-syndromic while 30% syndromic with 
other associated clinical features (Morton 1991). The proportion of children with 
permanent significant hearing impairment present since the neonatal period is 
reportedly 80-90% (Davis et al. 1997; Kuhl and Williams 1992). Hearing loss 
before the development of speech and language is termed prelingual deafness. A 
number of studies describe an intricate link between hearing impairment and the 
sensory development of the infantile brain and neurosensory netwoks (Ruben and 
Schwartz 1999; Sininger, Doyle and Moore 1999; Stockard-Pope 2001; Hannon 
2003). Late diagnoses of prelingual deafness result in deleterious effects that 
include psychosocial, educational and economic aspects both from an individual 
and societal viewpoint (Bess, Dodd Murphy and Parker 1998; Ruben 2000; 
Schroeder et al. 2006). Given these pervasive individual disadvantages and the 
significant economic burden to society efforts at early detection of hearing loss 
slowly gained importance. A greater emphasis on screening and identification of 
hearing impaired children evolved to mitigate the harmful consequences on 
language, speech and overall mental development. While Wilson and Junger 
(1968) laid out the 10 basic principles of screening that in a review of hearing 
screening in children was also adapted by Davis and co-workers (1997). Based on 
these principles, epidemiological studies at the local level are deemed necessary 
to determine the value of screening and for proper planning of service provision. 
The availability and accuracy of objective testing and proper intervention following 
the diagnosis need to be established. Likewise, cost and effectiveness of any 
hearing screening should be examined on a case type basis to maximize benefit. 
This cost-benefit of screening will have to be justified before public financing of this 
secondary prevention measure is made available more so in an era of stiffly 
competing health interventions that need financial support. This issue is especially 
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significant in developing countries where the incidence of hearing impairment 
especially among children have reportedly been higher but resources are limited. 
 
Risk factors and Objective Screening  
The Joint Committee on Infant Hearing in 1982 already recognized the problems 
related to delayed diagnosis of childhood deafness and recommended 
identification by the age of 3 to 6 months. It updated several times a list of high risk 
factors or high risk registry (HRR) for neonates and infants  whereby identification 
of hearing loss would be of paramount importance (JCIH 1982; JCIH 2000; JCIH 
2007). In 1993, along with the United States National Institutes of Health it 
published a consensus statement which emphasized the need for early detection 
of hearing loss by the use of objective testing like otoacoustic emission (OAE) 
testing and auditory brainstem response (ABR) testing (National Institute on 
Deafness and Other Communication Disorders Consensus Statement 1993). In 
1995, the World Health Assembly in its resolution 48.9 exhorted countries to set 
up national plans for the prevention and early detection of hearing loss among 
children (WHO 1995). There was evidence that with risk screening alone about 
42% of hearing impaired children will be likely missed such that objective testing 
for hearing loss must be universally applied (Wrightson 2007). On the other hand 
The Wessex Universal Neonatal Screening Trial Group (1998) diagnosed those 
with  permanent childhood hearing loss who had  risk factors such as stay in the 
NICU or low birth weight, infections in only about 8 %  giving further support to the 
need for objective screening  to be applied universally to all newborns.  
OAE testing entails the introduction of clicks or tones in the ear canal while 
“cochlear  echoes”  detected  by  a  sensitive  microphone  in  turn  would indicate good 
outer hair cell motility in hearing ears. The thresholds at which responses are 
detected are 30 dB for transient evoked OAE and 40 dB for distortion product OAE 
in which two tones are used. ABR testing looks at the electrophysiological 
responses elicited by transient acoustic stimuli such as tone bursts or clicks that 
are detected by surface electrodes placed on the forehead and near the ears.  It 
looks at the integrity of the neural pathways from the ear to the brainstem with 
Wave I response coming from the distal eight nerve, Waves II to IV from the 
proximal end of the eight nerve to the caudal pons, the trapezoid body and the 
superior olivary complex while Wave V generally comes from the lateral lemniscus 
as it approaches the inferior colliculus, is the most robust of all waves such that 
the threshold of hearing is usually based on this particular wave (Hall JW III 2007). 
Automated ABR devices or AABR that ascertains the presence of a Wave V 
response at 35 dB HL have confirmed failure rates as low as 2% in a healthy baby 
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population and only 4% in intensive care nursery infant population (Stewart et al. 
2000). AABR is more sensitive in detecting a hearing loss including those that may 
be missed by OAE such as auditory neuropathy or hair cell dys-synchrony (Rance 
G et al. 1999) which may affect up to 8.44% of profoundly deaf children (Foerst 
2006; Ngo et al. 2006). Early intervention with early detection of hearing loss 
depends on objective OAE or AABR followed by diagnostic confirmation by ABR. 
Auditory Steady State Response (AASR) is a test that uses FM modulated stimuli 
in order to binaurally assess the auditory system and  provides frequency specific 
information valuable for the estimation of auditory thresholds particularly those 
with severe to profound hearing loss (Stapells et al. 1984; Rance G and Rickards 
F 2002).  
Developed countries variably adopted different newborn hearing screening 
protocols for carrying out this early identification of hearing loss. In the United 
Kingdom the mandatory screening by health visitor distraction test of all babies at 
eight months eventually gave way to universal newborn hearing for the early 
detection of hearing loss within three months of birth and early intervention by the 
age of six months (Davis et al. 1997). While the first screening could be carried out 
while the baby was still in the hospital a second screening utilizing either an 
otoacoustic emission test or automated auditory brainstem response test within 
three months have become the norm. A second failed screening result with either 
OAE and AABR was followed by a diagnostic ABR. Before universal newborn 
hearing screening (UNHS) was instituted the median age of identifying hearing 
loss in children varied from 10.4 months to 43.2 months in the U.S, and some 
European   countries   in   the   early   1990’s   (Harrison,   Roush   and Wallace 2003; 
Marttila and Karikoski 1996; Parving 1999; Watkin, Baldwin and McEnery 1991 ) 
but now stands at 3 months in most of the developed world with UNHS 
programmes. This  is in contrast to the experience in developing countries where 
parental   suspicion   prompted   by   a   child’s   inappropriate   response   usually  
constitutes the reason for consultation at a mean age of about 22 months (Mukari 
Vandort, Ahmad, Saim and Mohamed 1999; Olusanya, Luxon and Wirz 2006). 
Last year, 97.4% of babies born in the U.S. have been screened which was a 
significant increase from the 46.5% reported in 1999. About 1.6% did not pass the 
final or most recent examination. Of those who did not pass the initial screen a 
diagnosis of whether there was hearing loss or not could be obtained in 68.4% 
before 3 months of age. Of those with hearing loss a quarter weighed less than 
2500 grams with the same proportion having one or more other developmental 
disabilities (Center for Disease Control  and Prevention 2012). 
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Hearing aids can be fitted between 3 to 6 months in most instances. Early 
intervention at around six months  were found to correlate well with better reading 
compr ehension and speech and language development (Yoshinaga-Itano et al. 
1998). There may well be other factors than early fitting of hearing aids or even 
cochlear implantation such as the auditory verbal training, audiological support 
and commitment of the parents and the family, presence of other disabilities as 
well as the ultimate choice of mode of communication that would greatly impact on 
outcomes. Some studies have reported a correlation between the presence of 
GJB2 mutation and outcome following cochlear implantation suggesting that 
genetic screening services would be clinically valuable. Though this is now carried 
out in some developed countries more studies will be needed to ascertain that 
such mutations are consistently responsible for the majority of congenital hearing 
loss and that this genetic screening will be clinically valuable in predicting 
outcomes and further aid genetic counseling.  
 
Challenges of Hearing Screening in a Developing Country like the 
Philippines 
Of the 6.5 billion people in the world about 5.3 billion live in developing countries. 
Population growth rates continue to rise in some of these countries in Asia, Africa 
and Latin America. The World Health Organization (WHO) estimated that two 
thirds of those with severe to profound hearing loss live in developing countries 
(Kumar 2001). Classification of countries whether developed or developing 
depends on several indices (GNI), gross national income per capita (lower income 
group cut off at $3255); Human Development Index (HDI) of 0.8 or GINI Index 
ideally at 0 with equal income distribution).   In  2010,  The  Philippines’  HDI  at  0.64  
ranked 112th among  187 countries surveyed putting it at medium development 
category, a GDP per capita of $3600 (Lower middle income economy <$3855) 
with expenditures for health pegged at 1.3% of GDP versus the 5% 
recommendation of the WHO (UNDP 2012).  
In the Philippines, the path towards an efficient and systematic universal screening 
for newborns and early detection of hearing loss in infants therefore remains to be 
a daunting task. Despite the fact that structured educational programmes in 
audiology have been instituted in two universities since 1999, most of the 
graduates get employment in other countries with better salaries and professional 
growth opportunities. An established programme on speech pathology previously 
offered in the national university (University of the Philippines) continues to lose its 
graduates to foreign employment (Cheng, Olea and Marzan 2002). It recently was  
joined by a private university (University of Santo Tomas) in offering  a  bachelor’s  
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degree in speech and language pathology and it is hoped that there will be more 
who will decide to stay to augment the number of trained speech therapists. 
Notable also are the geographic (the Philippines is an archipelago of 7000 
islands), economic, infrastructure problems (audiologic equipment not readily 
available in most hospitals) with less than 24 hospitals within Manila having OAE 
or ABR equipment (CONHSCA 2006). Universal newborn hearing screening 
protocols from developed countries needed to be investigated with respect to local 
adaptability. In fact, though few tertiary hospitals offered targeted OAE testing 
since 1996 none of the government hospitals could offer this given the lack of 
equipment and trained personnel. The usual protocols in developed countries 
needed modification given that the number of births in hospitals comprise only 
40% with more home deliveries. This is especially challenging in a country like the 
Philippines with a population of 95 million and where the population grows at 
1.87% whilst infant mortality rate is 18.75 per 100 live births (Philippines Fact 
Sheet 2012). 
 
Scope and Objectives of this Thesis 
As discussed earlier there was first the need to establish baseline epidemiologic 
data regarding the risk of neonatal hearing loss in a national tertiary academic 
referral center such as the Philippine General Hospital as there were no published 
epidemiologic data in the country on the prevalence of hearing loss among 
newborns with or without risk factors  (Quintos et al. 2003; Chiong et al. 2004). 
Clearly the neonatal intensive care unit of a hospital where the sickest babies 
maybe found provided a good starting point at which the percentage of babies with 
risk of hearing loss could be established is the subject for discussion in Chapter 2. 
The associated risk factors for failing the evoked otoacoustic emission testing was 
investigated. Male gender and low birth weight emerged as significantly 
associated with a fail result which was found in up to 29% of NICU babies. 
Etiologic basis for profound deafness was noted in those undergoing cochlear 
implantation with 32% with maternal rubella and other infections (labyrinthitis, 
meningitis, chronic otitis media and ototoxicity comprising about 50% of the 
causes to be preventable (Chiong et al. 2012b). This is consistent with the report 
by Alberti (1996). This highlights the importance of primary prevention of hearing 
loss with good prenatal and perinatal care, increased public awareness and 
maternal education. While such preventative programs are limited the significance 
of secondary prevention such as  hearing screening is heightened.  
Otoacoustic emissions (OAE) tests  employed in two stages in most of the centers 
could be adopted as specificity and sensitivity compared well to the diagnostic 
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ABR. Children were brought to our diagnostic unit at a much later age over 12 
months of age in the majority of cases ( Llanes and Chiong 2004) as discussed in 
Chapter 3. 
Two other related studies published from our center investigated 1) the value of 
ASSR and showed that 85% of very young children with flat or absent ABR 
responses had residual thresholds noted in frequencies 500Hz, 1kHz, 2kHz and 
4kHz (Tan et al. 2009)  and  2)  the  validity  of  a  human  voice  “BAAH”  reflexive  test    
and its accuracy in detecting a hearing loss compared to OAE among infants aged 
6 months and below (Garcia et al. 2012). While the former allowed more precise 
hearing aid fitting and objective choice of which ear to amplify (limited funds 
preclude bilateral hearing aids), the latter gives an alternative method that can be 
carried out in the communities for newborn and infants by trained community 
health workers.)  
That hearing loss in infants results in significant delays in development is well 
accepted. In Chapter 4 not only do we establish the prevalence of profound 
bilateral hearing loss at 1.38 per 1000 in a population based study but we also 
discuss evidence regarding the  effects of even a mild or unilateral hearing loss on 
overall mental development using the   Griffith’s   scale   that   is   used   by  
developmental pediatricians in evaluating young children over a period of two 
years from birth. That mild or unilateral permanent hearing loss can also lead to 
difficulties with language, psychosocial and educational  development is further 
supported by the findings in this study (Chiong et al. 2007).  
 
Other Risk Factors: Auditory Effects of Maternal Exposure to Pesticides  
Most developing countries rely on agriculture as the main fuel for the economy and 
potentially hazardous chemicals are used not only to combat pests but also to 
increase crop yields, for control of vector borne diseases and parasites among 
livestock. That low level and long term exposure to pesticides can cause diverse 
health effects is well known ( WHO/UNEP 1990). In the rural areas of developing 
countries insecticides comprise the greatest proportion of pesticides because of 
their cheaper cost (Araki, Yokoyama and Murata 1997). Both peripheral and 
central nervous system damage from organophosphates and pyrethroid products 
were noted  especially among workers with a 7.58 relative risk of central auditory 
dysfunction measured through duration and pitch pattern sequencing tests 
(Teixeira and Brandao 1998; Teixeira, Augusto and Morata 2002). However, fetal 
outcomes of maternal exposure to these toxic products are less known.  
The substrate with which such pesticides have been commonly measured in 
adults include serum, blood, urine  but the incidence and levels of exposure 
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among dyads of  mother and child in an agricultural community in the Philippines 
proved that meconium was most sensitive in detecting fetal exposure to 
environmental  pesticides (Ostrea et al. 2008; Ostrea et al. 2009 ). In Chapter 5 
we describe in a similar cohort of children the possible effects of maternal 
exposure to environmental toxins to the auditory system by correlating the 
presence of different pesticides on matrices such as maternal or infant hair, 
umbilical cord blood and meconium and hearing loss. ABR thresholds and 
latencies were measured in both the exposed and non-exposed groups in order to 
look at possible neurotoxic or auditory effects of these known toxic products 
(Chiong et al. 2012a).  
 
Cost Benefit Analysis of Universal newborn hearing Screening in the 
Philippines 
Schroeder (2006) reported that there are increased costs for health and social 
services and education in hearing impaired children compared to their hearing 
peers. Nonetheless, early detection and intervention have been reportedly cost 
beneficial in the long term from a societal point of view (Porter, Neely and Gorga 
2009) but likely affected by the selection criteria used in the UNHS programme. 
The United States Preventive Services Task Force (USPSTF) recommended 
screening for hearing loss in all newborns given that early identification and early 
intervention showed benefits irregardless of the degree of hearing loss (Kennedy 
2006; Appuzo and Yoshinaga-Itano 1995; Moeller 2000). When diagnosed after 
the age of six months there was correlation between the language abilities and the 
degree of hearing loss but not when diagnosed before the age of six months 
(Yoshinaga-Itano 2003). Keren and co-workers (2002) modeled similar language 
benefits for a hypothetical cohort of 80,000 infants and demonstrated the cost-
effectiveness of UNHS. In a public hospital in Brazil, the annual cost of the 
universal newborn hearing screening programme was US$ 26,940.47 with about 
11,466 screened over three years and 11 children diagnosed with hearing loss or 
a prevalence of 0.96:1000 (Bevilacqua et al. 2010).  
In a study by Neumann (2006) in Germany the cost for a child with severe hearing 
loss amounted to Euros 13,438; 8241 Euros for risk screening only and 4760 
Euros without systematic screening. However the cost of education, speech 
training will tend to reverse the conclusion as education within the first 16 years of 
life with hearing loss would have amounted to 125,778 Euros  in UNHS, 140,605 
Euros for risk screening and 155,944 Euros without screening.  
Given the cost of screening it seems pragmatic to relegate developing countries to 
the use of the HRR and screen only high risk newborns and infants. However, 
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Olunsaya highlighted the fact that this appeal of  targeted screening in resource 
limited regions such as the Sub-Saharan Africa and Southeast Asia (to which the 
Philippines belong) entails diverse operational constraints that  could significantly 
reduce its cost effectiveness. The baseline prevalence (risk) of hearing loss will 
likely affect the estimated economic burden in a universal strategy as shown by 
Burke et al. (2012) as illustrated when comparing India with the U.K. in his study 
that utilized a decision tree approach. In chapter 6 we describe the cost benefit of 
a universal newborn hearing screening programme in the Philippines (Chiong and 
Santos-Cortez 2012) that utilized the data from earlier studies in chapters 3 and 4 
regarding the prevalence rate and accuracy of OAE vis a vis the ABR. Incidentally, 
all these studies provided the evidence base that helped push for a law that 
mandates UNHS to be enacted in 2009 as Republic Act 9709 otherwise known as 
the Universal Newborn Hearing Screening, Prevention, Early Detection and 
Intervention Act (Appendix 1) signed by former President Gloria Macapagal-
Arroyo. The year 2010 saw the implementing rules and regulations approved by 
the Department of Health (Appendix 2) and the final manual of operations 
expected to be approved by the first quarter of 2013. The legislative mandate is 
expected to push UNHS in the communities where they are most needed. 
Aside from newborn hearing screening done to detect early the presence of 
congenital hearing loss some countries have introduced genetic screening as a 
way by which hearing loss might be detected early and looking at its etiologic 
basis. Chapter 7 describes the first attempt at looking at the genetic cause of 
congenital profound hearing loss among Filipinos. Genotypic-phenotypic 
correlation was done for two subjects found to have GJB2 mutations. No 
correlation with cochlear implant performance could be proven in this study 
however as the rate of GJB2 mutation was noted at 3.3% only). 
In summary, in the last ten years we did studies to look at the epidemiology of 
hearing loss, the age at identification, the risk factors involved, how both objective 
testing either by OAE, ABR or ASSR, and if other alternative behavioural testing 
could be utilized for the early detection and screening of childhood deafness.  
Maternal exposure to environmental toxic products and its possible effects on the 
auditory system was likewise investigated. Finally a cost benefit analysis of 
universal newborn hearing screening in the Philippines could be undertaken based 
on data culled from the studies at hand. This thesis further exemplifies a 
developing country perspective on how research evidence can be used to 
translate to a national policy and legislation to address an important health issue 
with an intervention that takes into consideration the problems encountered in a 
resource limited setting. 
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Abstract 
 
Objective: 
To determine pass and refer rates, and identify risk factors relating to refer 
responses, in neonates screened using distortion-product otoacoustic emissions 
(DPOAEs). 
 
Material and Methods:  
A total of 435 neonates admitted to the neonatal intensive care unit (NICU) of the 
Philippine General Hospital between May and October 2000 were screened using 
DPOAEs within 48 h of admission.  
 
Results:  
The male:female ratio in the sample was 1.05. In total, 56% of neonates were born 
preterm, the mean birthweight was 2428.39+710.39 g and 8.9% weighed <1500 g. 
In total, 47.9% were delivered by Caesarian section and 44.9% were delivered 
vaginally. Almost 14% of neonates had 1-min Apgar scores of <6, and 4% had 5-
min Apgar scores of <7. Approximately 95% of neonates had a poor perinatal 
history. Using pediatric aging it was noted that 46% of these neonates were born 
preterm, and 30.4% were small for gestational age. At least one neonatal disease 
was found in 42% of neonates, whilst 95.7% had to be given medication. The 
bilateral refer rate was 29.1%. Two-by-two analysis of risk factors for hearing loss 
and DPOAE measurements showed that only male sex seemed to have a 
significant association with a refer response. Neonates weighing <1500 g at birth 
showed a marginally significant association with a refer response (p = 0.07). All 
other neonates showed no crude association with DPOAE measurements.  
 
Conclusion:  
These preliminary data show that a high proportion of NICU patients may have 
poor outer hair cell function, and thus poor hearing. In order to develop an 
effective neonatal hearing screening program, further studies of prevalence and 
risk factors should be pursued in the same setting. Key words: distortion product 
otoacoustic emissions, neonatal hearing screening, risk factors.  
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Introduction  
 
In recent decades a great deal of effort has been expended in the development of 
hearing screening programs. Early identification of deaf children at the neonatal 
stage would result in early treatment and rehabilitation, and prevent language, 
developmental and social problems.1 The prevalence of bilateral hearing 
impairment does not vary much, as reported in various studies: (i) 2.18/1,000 
births per year1; (ii) 1.2/1,000 births per year over the period 1983-19882; and (iii) 1 
2/1000 well babies and 4-5% of neonates with one or more audiologic risk 
factors3, as summarized in the Joint Committee on Infant Hearing (JCIH) Position 
Statement in 19934. Early diagnosis of hearing loss has been made possible by 
means of auditory brainstem responses (ABRs) and otoacoustic emission testing. 
Universal neonatal hearing screening has been proposed and instituted in 
developed countries, in which even a single case of permanent hearing loss is a 
cause for concern. In spite of increased costs [screening of each infant may cost 
US$ 17-264, US$ 19.885 or US$ 24.482, and the cost of identifying 1 case of 
sensorineural hearing loss may range from US$ 22,1144 to US$ 56,0452 or US$ 
5,000-$ 17,7504, consensus statements supporting the need for universal neonatal 
hearing screening have been proposed by the different specialties and 
committees.4,6-8  
In most developing countries, such as the Philippines, both the government and 
the general population lack an awareness of the importance of preventing bilateral 
permanent hearing loss. The prioritization and allocation of resources for hearing 
prevention programs, if any exist, are lacking. Active case identification through 
hearing screening programs cannot be pursued if most patients with hearing loss 
are diagnosed at a later age, when treatment and rehabilitation may no longer be 
of value. Among local medical specialists, however, there has been much concern 
about the possible effects on the quality of life of neglected cases of bilateral 
permanent hearing loss. There is a need to conduct local studies on the 
epidemiology of hearing loss and the validity of different hearing screening 
equipment in our setting, in order to be able to design an available, appropriate 
and affordable hearing screening program.  
For the last 10 years, diagnostic ABR testing has been employed to screen babies 
for hearing loss on a referral basis in our Otorhinolaryngology department. Active 
ABR screening of babies in the neonatal intensive care unit (NICU) may not be 
feasible because it is time consuming and expensive. In contrast, otoacoustic 
emissions testing, which is less time consuming, automated and has great 
promise as a mass screening tool among neonates, has yet to be introduced in 
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our country. This preliminary study aims to determine the pass and refer rates for 
distortion product otoacoustic emissions (DPOAEs) testing among neonates in the 
NICU and the factors associated with refer responses.  
 
 
Material and methods 
 
All neonates admitted to the NICU between May and October 2000 were 
subjected to DPOAE testing using the Welch Allyn® AudioPath EOAE Screener 
29230, after obtaining maternal consent. A trained research assistant monitored all 
admissions using the NICU logbook. Before each test, the screener performed a 
calibration test. The background noise was measured and if there was a 10 dB 
difference detected in response to two tonal stimulations, the machine auto-
matically  showed  a   ‘‘pass’’   response.  Otherwise,  a   ‘‘refer’’   response  was  shown.  
‘‘Fail’’   responses  necessitated   checking   for   vernix   or   obstruction   in   the   canal,   or  
inappropriate probe fitting. The hearing test was repeated 24 h later once the 
vernix or cerumen in the canal had been cleared. Determinations were done in the 
afternoon to minimize noise. Appropriate ear probe tips were used to fit the ears of 
the subjects. The following variables were determined: pass and refer rates for 
DPOAE; birthweight; gestational age; sex; maternal factors; perinatal factors; 
method of delivery; Apgar scores at 1 and 5 min; pediatric aging; medication; and 
history of rubella, syphilis, TORCH (toxoplasmosis, other, rubella, cytomegalovirus 
and herpes), mumps and chickenpox. Data from the hearing screening and the 
patient’s  charts  were  retrieved  using  a  data  abstraction  sheet.  The  data  gathered  
were encoded, processed and analyzed using EPI-INFO software, version 6.05.  
 
 
Results 
 
A total of 435 neonates were screened in the NICU during the study period (Table 
1). Seven had incomplete data and were excluded from the analysis. There were 
approximately equal numbers of boys and girls (male:female ratio 1.05). In total, 
56% of neonates were born preterm, the mean birthweight was 2428.39+710.39 g 
and 8.9% weighed <1500 g. In total, 47.9% were delivered by Caesarian section 
and 44.9% were delivered vaginally. Almost 14% of neonates had 1-min Apgar 
scores of <6, and 4% had 5-min Apgar scores of <7. Approximately 95% of 
neonates had a poor perinatal history. Using pediatric aging it was noted that 46% 
of these neonates were born preterm, and 30.4% were small for gestational age. 
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At least one neonatal disease was found in 42% of neonates, whilst 95.7% had to 
be given medication (antibiotics in almost all cases). Maternal diseases that may 
cause hearing loss in neonates included rubella (n = 9; 2.1%), TORCH (n = 2; 
0.5%), syphilis (n = 1; 0.2%) and trauma (n = 1; 0.2%).  
 
 
Table 1:  Risk factors for hearing loss among neonates  
 
Neonatal risk factor N (%) 
Gestational age <37 weeks 
Birthweight <1500 g 
Caesarian section 
Apgar score at 1 min in range 1-5 
Apgar score at 5 min in range 1-6 
Poor perinatal history (at least one of hypotonia, 
jaundice, poor lacrimation, cyanosis, birth trauma, cord 
coil, meconium staining) 
Small for gestational age 
Presence of neonatal disease 
Medication administered 
Maternal age <33 years 
178/406 (43.8) 
  39/428 (8.9) 
199/421 (47.1) 
  58/360 (13.9) 
  17/401 (4.1) 
346/365 (94.8) 
 
 
111/369 (30.1) 
133/347 (38.3) 
289/302 (95.7) 
  86/155 (55.5) 
 
 
 
 
Figure 1: Distribution of results of DPOAE measurements among neonates 
 
DPOAE measurements showed that the bilateral refer rate (which connotes 
permanent  congenital  hearing   impairment)  was  ≈29%,  and   the  overall   refer   rate,  
which  includes  unilateral  refer  responses  in  either  ear,  was  ≈49.2%  (Figure  1).   
Two-by-two analysis of risk factors for hearing loss and DPOAE measurements 
showed that only male sex seemed to have a significant association with a refer 
response (Table 2). Neonates weighing <1500 g at birth showed a marginally 
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significant association with a refer response (p = 0.07). All other neonates showed 
no statistically significant association with DPOAE measurements.  
 
Table 2: Association of DPOAE pass and refer responses with risk factors among 
neonates 
 
Risk factor Refer;  
n(%) 
Pass;  
n(%) 
p Odds ratio  
(95% CI) 
Male gender 
Gestational age <37 weeks 
Apgar score at 1 min in range 1-5 
Apgar score at 5 min in range 1-6 
Birthweight <1500 g 
Poor perinatal history 
Caesarian section/forceps 
Small/large for gestational age 
Presence of neonatal diseases 
Medication administered 
Maternal age <33 years 
Presence of bleeding episodes 
Pre-eclampsia 
Presence of maternal diseases 
121 (55.3) 
  79 (44.4) 
  25 (43.1) 
    7 (41.2) 
  24 (63.2) 
203 (49.8) 
113 (48.9) 
  61 (49.2) 
  67 (46.2) 
131 (45.3) 
131 (45.3) 
  12 (44.4) 
  29 (49.2) 
  41 (41.2) 
 
  98 (44.7) 
  99 (55.6) 
  33 (56.9) 
  10 (58.8) 
  14 (36.8) 
205 (50.2) 
118 (51.1) 
  63 (50.8) 
  78 (53.8) 
158 (54.7) 
158 (54.7) 
  15 (55.6) 
  30 (50.8) 
  44 (51.8) 
 
0.012 
0.165 
0.31 
0.495 
0.073 
0.514 
0.825 
0.35 
0.352 
0.25 
0.25 
0.56 
0.94 
0.41 
 
1.63 (1.09-2.45) 
0.76 (0.50-1.15) 
0.75 (0.41-1.36) 
0.71 (0.24-2.09) 
1.86 (0.89-3.94) 
1.36 (0.49-3.83) 
0.96 (0.64-1.44) 
1.23 (0.77-1.95) 
0.88 (0.56-1.38) 
0.52 (0.14-1.82) 
0.52 (0.14-1.82) 
0.79 (0.33-1.87) 
0.98 (0.54-1.79) 
0.75 (0.36-1.57) 
 
 
 
Discussion 
 
A high percentage of bilateral refer responses was found among neonates in this 
study; this is comparable to the result found in a parallel study conducted locally 
(unpublished work), but higher than those reported in other studies: 6.67%14, 10%9 
and 5/1000.10 This may be due to very high-risk neonates being admitted to the 
NICU or increased false-positives resulting from the performance of DPOAE 
testing in the nursery setting, with a relatively high level of background noise. 
Almost 95% of NICU patients had a poor neonatal history, with half having one or 
more risk factors associated with hearing loss. Babies admitted to our NICU may 
be more seriously ill compared to those in studies conducted in developed 
countries (family history of hearing impairment, 6.6%; perinatal infection, 3.8%; 
birthweight <1500 g, 1.2%.9). False-positive values reported from OAE testing 
include 3.5%5, 6.63%10, 16.2%11 and 11-35%12. These cases may be mislabeled 
‘‘refer’’   and  cause  undue  anxiety   to   the  parents,  even   though this worry may be 
unsubstantiated.13 Parents should be told that a refer response only means that 
their child is scheduled for OAE retesting and ABR screening.  
Risk factors that were studied but not found to be significantly associated with a 
refer response included those used in the JCIH registry. This may be due to two 
reasons: (i) only a certain proportion of high-risk babies will have hearing loss, 
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even with the presence of risk factors; and (ii) the inadequate sample size in this 
study, considering the relatively low prevalence of hearing loss, even among high-
risk neonates. Further studies utilizing a larger sample and multivariate techniques 
need to be done in order to determine a model of predictors that can predict 
hearing loss among neonates with a refer response. It is necessary to determine 
the validity of hearing screening tests such as DPOAE. Significant barriers to the 
performance of ABR testing in a large sample are that it is time consuming, difficult 
to do and requires sedation of the subject12; however, it is necessary for 
comparison with DPOAE results. In a local study (unpublished work), involving 100 
infants with bilateral refer responses from DPOAE testing, 12 were submitted for 
re-screening,  9  of  whom  (75%)  converted  to  ‘‘pass’’.  Preliminary results on referral 
data from January to July 2002 at our Ear Unit show good concordance between 
DPOAE and diagnostic ABR. 
Only male gender was significantly associated with a refer response, in 
accordance with the finding of a significant sex effect at 4 kHz, where the mean 
amplitude of DPOAEs was higher in female than male babies.13 Low birthweight, 
poor perinatal history and being small for gestational age had odd ratios above the 
null (>1), consistent with other findings, but were not found to be statistically 
significant. The aim of universal neonatal hearing screening is to identify neonatal 
hearing loss before the age of 3 months, so that rehabilitation can be performed 
before the age of 6 months.7 This is ideal in our setting, considering the costs that 
may be incurred. However, because of the inherent poor follow-up of patients in 
our hospital, this may not be feasible at this time. Initially, in lieu of retesting of 
OAE failures, the presence of a constellation of validated risk factor predictors can 
be used to determine whether babies should be subjected to diagnostic ABR 
screening. Proper follow-up of patients should be ensured, as loss to follow-up is 
the primary reason for failure to confirm hearing loss and institute rehabilitation 
before children reach the age of 1 year.14  
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Abstract 
 
Objective:/ 
Evoked otoacoustic emissions (OAEs) and diagnostic auditory brainstem 
responses (ABRs) were determined in 379 high-risk children referred for hearing 
screening. 
 
Material and Methods:/ 
This was a retrospective, cross-sectional study. The records of 379 children 
referred for hearing screening between January 2002 and March 2003 at the Ear 
Unit of the Philippine General Hospital were evaluated. 
 
Results:/ 
Of the 379 children, 53.6% were male and 46.4% were female and the mean age 
was 41+47 months. The age distribution was as follows: </12 months, 32.2%; 12-
24 months, 52.2%; and >/24 months, 11%. Out of 229 right and 232 left ears, 111 
(48.5%)   and   112   (48.3%)   had   ‘‘pass’’   responses   and   113   (49.3%)   and   116  
(50.5%)   had   ‘‘refer’’   responses,   respectively.   Five   right   and   four   left   ears   had  
‘‘noise’’  responses.  Out  of  266  right  and  209  left  ears,  the  ABR  results  showed  72  
(27.1%) and 30 (14.4%) with normal auditory pathways and 194 (72.9%) and 179 
(85.6%) with abnormal auditory pathways, respectively. Of the 131 children whose 
parents gave their consent for concomitant OAE and ABR testing, agreements 
were observed between the two tests in terms of classifying the results as normal 
or abnormal of 78.9% (K = 0.51; p = 0.00) in right and 78.6% (K = 0.51; p = 0.00) in 
left  ears.  When  the  children  were  classified  as  either  ‘‘with  hearing  loss   -/bilateral 
abnormal  ABRs’’  or  ‘‘at  least  one  normal  ABR’’,  there  was  an  observed  agreement  
of 81% (K=0.6; p=0.00). OAEs had a sensitivity of 76.9% (95% CI 66.7-84.8%) and 
a specificity of 90% (95% CI 75.4-96.7%). 
 
Conclusion:/ 
There is good concordance between OAE and ABR results among high-risk 
children referred for hearing screening. Key words: auditory brainstem response, 
evoked otoacoustic emissions, hearing screening, sensitivity, specificity. 
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Introduction  
 
With heightened awareness of the importance of preventing hearing loss at an 
earlier age, universal neonatal hearing screening has been advocated by many 
institutions worldwide. This would enable health professionals to identify cases of 
hearing loss earlier and therefore institute treatment and rehabilitation for patients 
identified as having hearing loss before irreversible consequences could ensue. 
Since 2000, our institution has used otoacoustic emissions (OAEs) and auditory 
brainstem responses (ABRs) to evaluate the hearing status of high-risk children.1 
At present, universal hearing screening is still not practicable given the difficulties 
of establishing a program, which requires logistic and financial resources. Thus, 
hearing screening of high-risk children is the responsibility of the Ear Unit, which 
receives referrals for hearing evaluation from pediatricians and other otorhino-
laryngologists both within and outside the hospital. 
Evoked OAEs and ABRs each have advantages and disadvantages in hearing 
screening, and the following parameters should be considered: (i) the ease of 
testing and obtaining results; (ii) cost; and (iii) technician dependence. In terms of 
reliability for screening, the diagnostic ABR remains the preferred test, with OAE 
testing as the initial investigation, as evident in most universal hearing screening 
protocols.2,3 Thus,  a  ‘‘refer’’  response  from  OAE  testing  will  be  followed  by  an  ABR  
test for confirmation, considering that false-positive and -negative responses may 
occur with OAE testing. 
In our setting, where patients often want to optimize their spending, a single, 
reliable, accessible, non-invasive and valid hearing test is usually desired to 
minimize the inconvenience and discomfort to patients, and in particular children. 
Determining the concordance between OAE and ABR testing, and identifying 
cases where non-agreement occurred, might be helpful in planning a more 
efficient flow of patients and may assist in identifying patients who are likely to 
have or to develop hearing loss with minimum cost. We aimed to determine the 
concordance between OAE testing and ABRs for assessing the hearing status of 
children referred for hearing evaluation at a tertiary institution.  
 
 
Material and methods 
 
The records of all patients referred to the Ear Unit for hearing screening between 
January 2002 and March 2003 were reviewed, where hearing status was 
assessed using both OAEs and ABRs. For every patient referred for hearing 
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evaluation, both OAE and ABR testing were usually performed, after obtaining 
consent from the parents and/or guardian. Otherwise, only the procedure (either 
OAE or ABR) requested by the referring otorhinolaryngologist was performed.  
All procedures were performed at the Ear Unit, which provides a quiet and 
conducive area for testing. OAE testing was done as previously reported1, and 
ABR testing was done using the Pilot ABR Evostar 2/1 machine, after allowing the 
patient to sleep. Either diphenhydramine hydrochloride or chloral hydrate was 
used to sedate irritable or younger patients.Data were extracted from the request 
form, and included sex, age, diagnosis, OAE results and ABR readings. The 
results were analyzed using EPI-INFO 6.05 and SPSS (Version 9.05) software. 
 
 
Results 
 
A total of 229 right and 232 left ears were subjected to OAE testing, while 266 right 
and 209 left ears underwent ABR testing. The majority of the referrals were for 
speech delay, suspected hearing loss or global developmental delay/autism/ 
mental retardation, etc. (Table 1). Of the 379 children, 53.6% were male and 
46.4% were female and the mean age was 41+/47 months. The age distribution 
was as follows: <12 months, 32.2%; 12-24 months, 52.2%; and > 24 months, 11%. 
Out   of   229   right   and   232   left   ears,   111   (48.5%)   and   112   (48.3%)   had   ‘‘pass’’  
responses  and  113  (49.3%)  and  116  (50.5%)  had  ‘‘refer’’  responses,  respectively.  
 
 
Table 1: Distribution of diagnoses of patients referred for hearing screening  
 
Diagnosis  n (%)  
Speech delay  79 (30.27)  
Suspected hearing loss  66 (25.29)  
Global developmental delay/  42 (16.09)  
mental retardation/autism/   
attention deficit hyperactive disorder   
Congenital rubella syndrome  15 (5.75)  
Prematurity  10 (3.83)  
Down’s  syndrome   10 (3.83)  
Cerebral palsy  10 (3.83)  
Ear malformation/microtia  9 (3.45)  
Post-meningitic hydrocephalus  5 (1.92)  
Meningitis  3 (1.15)  
Others  12 (4.58)  
Total  261 (100.0)  
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Five  right  and  four   left  ears  had  ‘‘noise’’  responses.  Out  of  266  right  and  209  left  
ears, the ABR results showed 72 (27.1%) and 30 (14.4%) with normal auditory 
pathways and 194 (72.9%) and 179 (85.6%) with abnormal auditory pathways, 
respectively. Figure 1 shows the distribution of ABR results (normal, mild, 
moderate,  severe  and  profound  hearing  loss)  and  the  number  of  ‘pass’  and  ‘refer’  
responses per category.  
 
 
 
Figure 1: Distribution of ABR results 
  
Of the 262 (n=131 children) ears subjected to both OAE and ABR testing, 152 
(58.02%) were referred with an abnormal ABR, and 54 (20.6% passed the OAE 
test and had a normal ABR, with a sensitivity (defined as the ability of the test to 
identify patients with hearing loss) of 77.9% (95% CI 71.3-83.4%) and a specificity 
(defined as the ability of the test to identify patients without hearing loss) of 80.6% 
(95% CI 68.8-88.9%) (Table 2).   In  our  setting,  a  patient  with  a   ‘‘refer’’   response  
has a 92.1% (95% CI 86.6-95.6%) chance of having abnormal ABRs, while a 
patient   with   a   ‘‘pass’’   response   has   a   55.7%   (95%   CI   45.2-65.6%) chance of 
having  normal  ABRs.   In   total,  43/262  ears   (16.4%)  had  a   ‘‘pass’’  OAE  response  
and abnormal ABRs, representing false-positive results, while 13/262 ears 
(4.96%) gave false-negative results.  
 
Table 2: Summary of sensitivity, speciﬁcity and predictive values of OAEs with ABR. 
Values given in parentheses are 95% CIs 
 
OAE Sensitivity  Specificity  PPV  NPV  k  
Right ear 
Left ear  
Both ears 
77.6% (67.8-85.1) 
78.4% (68.6-85.8) 
77.9% (71.3-83.4) 
81.8% (63.9-92.4) 
79.4% (61.6-90.7) 
80.6% (68.8-88.9) 
92.7% (84.2-97) 
91.6% (82.9-96.3) 
92.1% (86.6-95.6) 
55.1% (40.3-69.1) 
56.3% (41.3-70.2) 
55.7% (45.2-65.6) 
0.51 
0.51 
0.51 
PPV=positive predictive value; NPV=negative predictive value. 
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Of the 131 children whose parents gave their consent for concomitant OAE and 
ABR testing, agreements were observed between the two tests in terms of 
classifying the results as normal or abnormal of 78.9% (k=0.51; p=0.00) in right 
and 78.6% (k= 0.51; p=0.00) in left ears, with an overall agreement of 79% (k=0.51; 
p=0.00)   for  both  ears.  When   the  children  were  classified  as  either   ‘‘with  hearing  
loss*   bilateral   abnormal   ABRs’’   or   ‘‘at   least   one   normal   ABR’’,   there   was   an  
observed agreement of 81% (k=0.6; p=0.00). OAEs had a sensitivity of 76.9% 
(95% CI 66.7-84.8%) and a specificity of 90% (95% CI 75.4-96.7%). In total, 
70/131   children   (53.4%)   had   a   bilateral   ‘‘refer’’   response   together   with   an  
abnormal ABR (Table 3). Of these 70 patients, 10 used hearing aids and 39 had 
undergone speech therapy. Twenty of these (mean age 3.8 years) had baseline 
language assessment, 17 of whom (85%) were found to have delayed language 
development. 
  
Table 3: OAEs and ABRs for the 131 children whose parents gave consent for OAE and 
ABR testing. Values shown represent numbers of patients, with percentages in 
parentheses 
 
 ABR 
OAE With hearing loss Without hearing loss Total 
Refer 
Pass 
Total 
70 (53.4) 
21 (16) 
91 (69.5) 
4(3.1) 
36 (27.5) 
40 (30.5) 
74 (56.5) 
57 (43.5) 
131 (100) 
Observed agreement0.81; agreement due to chance= 0.53; k=0.6, p0.00; sensitivity=76.9% (95% 
CI 66.7-84.8%); specificity=90% (95% CI 75.4-96.7%); positive predictive value=94.6% (95% CI 
86-98.3%); negative predictive value=63.2% (95% CI 49.3-75.2%). 
 
 
Discussion 
 
In a setting in which there are various limitations in establishing an effective and 
affordable hearing program, the adoption of a universal hearing screening program 
has proven to be difficult, especially given the inherent problem of inadequate 
follow-up for most of our patients. Because of the high prevalence of bilateral 
hearing loss among babies with risk factors of ≈29%1, it is imperative to determine 
the value of OAE testing, in comparison with ABR, for screening during the last 10 
years. This may be valuable in planning an effective screening program for 
neonates and infants that may be applicable to most institutions nationwide. 
The majority of patients referred were aged 1-/2 years, and most presented with 
speech delay or hearing loss. This group of patients may represent cases where 
risk factors for hearing loss are unknown, indicating that there is still much work to 
be done to identify risk factors that may give clues as to the cause of hearing loss, 
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as well as predicting that a child may develop hearing loss. Congenital rubella and 
prematurity reflect the standard of prenatal care, and still pose risks to children. 
Ideally, in a given situation, hearing loss should be identified early enough in order 
to treat and prevent sequelae of speech delay. Thus, in many countries, 
identification of hearing loss is being advocated at the age of 6 months, to ensure 
early treatment and rehabilitation.2,3 In our type of population, without the benefit of 
universal hearing screening, the use of OAE testing alone, considering the 
difficulties inherent in recording an ABR, may be justified, with certain limitations. 
There seemed to be no difference between the right and left ears in terms of the 
parameters determined, and there was also no difference when both ears were 
analyzed together. Sensitivity and specificity were ≈77.9% and ≈80.6%, 
respectively. 
In this study, the concordance between OAEs and ABRs seems to be adequate 
for our purposes, and in determining validity of OAE as a screening tool against 
ABR, the performance of OAE (sensitivity, 77.9%; specificity, 80.6%) may be 
acceptable as a screening tool among children referred for suspicion of hearing 
loss, although it is worse compared to most previous studies.4 With the kind of 
population we serve, the likelihood  that  a  patient  with  a  ‘‘refer’’  response  will  have  
hearing loss (positive predictive value) is 92.1%. In contrast, the likelihood that a 
patient   with   a   ‘‘pass’’   response   will   not   have   hearing   loss   (negative   predictive  
value) is 55.7%. These data suggest that for most patients with risk factors for 
developing   hearing   loss   referred   to   our   unit,   a   ‘‘refer’’   response  may   be   reliable  
enough to warrant early intervention, with repeat testing using behavioral 
audiometry (visual reinforcement audiometry) being performed at an appropriate 
age. However, caution must be exercised in advising parents and/or guardians 
when   the   response   registers   as   ‘‘pass’’,   as   the   false positive rate is ≈16%. This 
may lead to children who really have hearing loss and need further testing being 
missed. This may be due to the limitations of the screening test or, if associated 
with an abnormal ABR, may indicate possible auditory neuropathy. In previous 
studies4, false-negative rates ranged between 5% and 13%. In recent reports5-7, 
patients with normal OAE results but abnormal ABRs were considered to have a 
condition called auditory neuropathy or dyssynchrony. In our study, 24 (9.2%) 
patients were noted to have these findings and further follow-up is therefore 
necessary. 
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Abstract 
 
Conclusion:  
Evoked otoacoustic emission (OAE) and auditory brainstem response (ABR) 
results for hearing screening among infants have good concordance. However, 
good correlation with the Griffiths Developmental Scales remains to be desired. 
 
Objective:  
To correlate hearing screening outcomes of a cohort of infants with developmental 
outcomes at 6 and 12 months.  
 
Subjects and methods: 
 A cohort of pregnant women was identified in several communities in a rural area 
(Bulacan province) from April 2002 to February 2003 as part of a population-based 
study determining maternal exposure to pollutants and infant outcomes, with a 
total follow-up of 2 years. Pregnant mothers were identified and followed up until 
delivery at a secondary, provincial hospital. Hearing screening was performed with 
OAEs and ABR. Mental development of infants was assessed at 6 and 12 months 
using Griffiths Mental Developmental Scales - locomotor, personal-social, hearing 
and speech, hand and eye coordination, performance tests.  
 
Results:  
Among the 1086 babies recruited, there were 724 with hearing assessment. Of 
these 724 babies, 565 had both OAE testing and  ABR. Overall in 1130 ears, OAE 
and ABR testing showed an observed agreement of 99%, agreement due to 
chance of 96%, and kappa agreement of 79% (p=0.00) in diagnosing bilateral 
hearing losses. OAEs had a sensitivity of 86.4% (95% CI 64-96.4%) and a 
specificity of 99.4% (95% CI 98.6-99.7%). At the end of the study, there were 
708/724 (97.8%) infants with normal hearing, 7/724 (1.0%) with unilateral hearing 
loss, 8/724 (1.1%) with bilateral mild hearing loss, and 1/724 (0.1%) with bilateral 
profound hearing loss, who demonstrated consistent mental delay throughout.  
Follow-up rates for developmental examinations at 6 and 12 months were 98% 
and 81.25%, respectively. In these groups, there were 8 (1%) infants at 6 months 
and 18 (2.4%) at 12 months with developmental delay (Griffiths Mental 
Developmental Scales).  
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Introduction  
 
The advent of new and affordable technology over the past years has helped to 
jumpstart newborn hearing screening programs worldwide, even in developing 
countries. Awareness among health practitioners and the public of the importance 
of hearing have increased 10-fold because of these concerted efforts to identify 
babies with hearing loss as early as possible, and in turn, provide early treatment 
and rehabilitation.  
In our setting over the past 5 years, a number of hospitals have carried out 
newborn hearing screening programs, the majority of which were instituted in 
public  and  private  tertiary  hospitals  in  the  nation’s  capital.  However,  these  applied  
varied protocols and in the majority follow-through refer rates have been 
unreported but generally not good. Diagnostic technologies like otoacoustic 
emissions (OAEs) and auditory brainstem response (ABR) may still be relatively 
costly, more so with hearing rehabilitation whether with hearing aids and/or 
cochlear implantation. However, bringing these technologies as well as their 
benefits to the community where the majority of underprivileged patients are to be 
found would really be more meaningful in our case, where only 38% of births are 
within health facilities.1 
Previous reports2,3 have documented our experience in starting hearing screening 
at a tertiary hospital, with both OAEs and ABR at the neonatal intensive care unit, 
where  there  was  a  29%  bilateral  ‘refer’  rate  but  on  follow-up a mere 10% to special 
populations referred to our Ear Unit for hearing assessment. It remains to be seen 
whether hearing screening with OAE and ABR in a community-based study will be 
as accurate. Moreover, correlation with accepted developmental instruments may 
be advantageous in order to assess the impact of hearing loss (if any) on 
development during the early years of life. In this paper, we present our 
experience in hearing screening of babies at the community level using OAE and 
ABR. Results of developmental assessment of hearing and speech were then 
correlated with hearing screening results.  
 
 
Subjects and methods  
 
A cohort of pregnant women was identified in several communities in a rural area 
(Bulacan province) from April 2002 to February 2005 as part of a population-based 
study determining maternal exposure to pollutants and infant outcomes, with a 
total follow-up of 2 years. Pregnant mothers were identified and followed up until 
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delivery at a secondary, provincial hospital. Newborns underwent hearing 
screening with OAE (Welch Allyn® Audiopath EOAE Screener 29230) and ABR 
(Interacoustics EP15). Mental development of infants was assessed by a team of 
developmental pediatricians at 6 and 12 months using the Griffiths Mental 
Developmental Scales - locomotor, personal-social, hearing and speech, hand and 
eye coordination, performance tests.4 The Griffiths Mental Developmental Scale is 
a test instrument administered by pediatricians from birth until 8 years of age, and 
measures motor maturity and development, ability to cope with routine situations 
in everyday living, auditory and speech functions, hand and finger motor mobility 
and eye and hand coordination, body consciousness, physical activity, and 
memory.  
 
 
Results  
 
There were 450 (54.4%) males, 375 (45.4%) females, and 2 (0.2%) ambiguous 
babies. Among the 1086 babies recruited, 724 underwent hearing assessment. Of 
these 724 babies, 565 had both OAE and ABR testing. Overall in 1130 ears, OAE 
and ABR testing showed an observed agreement of 99%, agreement due to 
chance of 96%, and kappa agreement of 80% (p=0.00) in diagnosing bilateral 
hearing losses. OAEs had a sensitivity of 86.4% (95% CI 64-96.4%) and a 
specificity of 99.4% (95% CI 98.6-99.7%) (Table 1-3).  
 
 
Table 1: Concordance of otoacoustic emissions (OAEs) and auditory brainstem response 
(ABR) among 565 children, right ears.  
 
 Auditory brainstem response 
Otoacoustic emissions >40 dB < 40 dB Total 
Refer 
Pass 
Total 
11 
0 
11 
2 
552 
554 
13 
552 
565 
Observed agreement = 0.99; sensitivity = 100% (67.9 - 100); agreement due to chance = 0.96; 
specificity = 99.6% (98.6 - 99.9); kappa = 0.91, p = 0.00; positive predictive value = 84.6% (53.7 - 
97.3); negative predictive value = 100% (99.1 - 100).  
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Table 2: Concordance of otoacoustic emissions (OAEs) and auditory brainstem response 
(ABR) among 565 children, left ears.  
 
 Auditory brainstem response 
Otoacoustic emissions >40  dB < 40 dB Total 
Refer 
Pass 
Total 
8 
3 
11 
5 
549 
554 
13 
552 
565 
Observed agreement = 0.99; sensitivity = 72.7% (39.3 - 92.7); agreement due to chance = 0.96; 
specificity = 99.1% (97.8 - 99.7); kappa = 0.66; p = 0.00; positive predictive value = 61.5% (32.3 - 
84.9); negative predictive value = 99.5% (98.3 - 99.9). 
 
 
Table 3: Concordance of otoacoustic emissions (OAEs) and auditory brainstem response 
(ABR) among 1130 ears, right and left.  
 
 Auditory brainstem response 
Otoacoustic emissions >40  dB < 40 dB Total 
Refer 
Pass 
Total 
19 
3 
22 
7 
1101 
1108 
26 
1104 
1130 
Observed agreement = 0.99; sensitivity = 86.4% (64 - 96.4); agreement due to chance = 0.96; 
specificity = 99.4% (98.6 - 99.7); kappa = 0.88; p = 0.00; positive predictive value = 73.1% (51.9 - 
87.6); negative predictive value = 99.7% (99.1 - 99.9).  
 
 
At the end of the study, based on the ABR threshold results there were 708/724 
(97.8%) infants with normal hearing, 7/724 (1%) with unilateral mild hearing loss, 
8/724 (1%) with bilateral mild hearing loss, and 1/724 (0.1%) with bilateral 
profound hearing loss, who demonstrated consistent mental delay throughout. 
Thus, the total prevalence of hearing loss documented was 2.2%.  
In all, 84% of babies were screened during the first 6 months of life, with 476 
(77%) from 0 to 3 months and 43 (7%) from 4 to 6 months, and a further 6% from 
6 to 9 months.  
Follow-up rates for developmental examinations at 6 and 12 months were 98% 
and 81.25%, respectively. In these groups, there were 8 (1%) infants at 6 months 
and 18 (2.4%) at 12 months with developmental delay (Griffiths Mental 
Developmental Scales).5  
There were 15 babies with hearing loss identified through ABR thresholds (Table 
3) with 1 baby having bilateral profound hearing loss. In this group, there were 
3/22 (14%) ears of babies with ABR thresholds >40  dB  HL,  with  ‘pass’  responses  
in the OAE testing (false negative). Three of seven with unilateral mild hearing loss 
and two of five with bilateral mild hearing loss had low development scores, while 
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the baby with bilateral profound hearing loss had consistently poor development 
scores. Correlation of the different subdomains with hearing impairment did not 
yield much in the way of conclusions. However, correlation of the hearing 
screening results with the subdomain of speech and hearing showed good 
correlation.  
The results of the study are summarized in Tables 4-9.  
 
 
Table 4: Distribution of patients according to age screened  
 
Age group (months) Frequency % 
1-3 
4-6 
7-9 
10-12 
> 12 
Total 
476 
43 
89 
5 
3 
616 
77.24 
6.97 
14.44 
0.80 
0.38 
100.0 
 
 
Table 5: Distribution of patients with abnormal hearing tests  
 
Patient Otoacoustic emissions ABR thresholds 
Unilateral mild Right Left Right Left 
1 
2 
3 
4 
5 
6 
7 
Unilateral moderate 
8 
Bilateral mild 
9 
10 
11 
12 
13 
14 
Bilateral profound 
15 
Refer 
Pass 
Refer 
Pass 
Pass 
Pass 
Refer 
 
Refer 
 
Refer 
Refer 
Refer 
Refer 
Refer 
Refer 
 
Refer 
Pass 
Pass 
Refer 
Pass 
Refer 
Refer 
Pass 
 
Pass 
 
Refer 
Refer 
Pass 
Refer 
Refer 
Refer 
 
Refer 
50 
20 
50 
20 
30 
40 
50 
 
80 
 
50 
50 
60 
50 
50 
60 
 
100 
40 
50 
30 
50 
50 
50 
40 
 
40 
 
60 
50 
50 
50 
50 
60 
 
100 
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Table 6: Distribution of hearing/language among patients with abnormal hearing tests  
 
Patient Hearing/language 
Unilateral mild SQ 6 
months 
Percentile 
6 months 
SQ 12 
months 
Percentile 
12 months 
1 
2 
3 
4 
5 
6 
7 
Unilateral moderate 
8 
Bilateral mild 
9 
10 
11 
12 
13 
14 
Bilateral profound 
15 
109 
100 
105 
114 
100 
100 
109 
 
109 
 
109 
109 
105 
105 
82 
91 
 
42.3 
71 
50 
62 
81 
50 
50 
71 
 
71 
 
71 
71 
62 
62 
13 
29 
 
0.5 
68 
71 
86 
107 
30 
40 
50 
 
98 
 
93 
94 
94 
104 
83 
- 
 
68.6 
2 
4 
19 
67 
14 
19 
21 
 
45 
 
35 
35 
35 
60 
14 
- 
 
2 
 
 
 
Table 7: Distribution of performance scores among patients  
 
Patient Performance 
Unilateral mild SQ 6 
months 
Percentile 
6 months 
SQ 12 
months 
Percentile 
12 months 
1 
2 
3 
4 
5 
6 
7 
Unilateral moderate 
8 
Bilateral mild 
9 
10 
11 
12 
13 
14 
Bilateral profound 
15 
96 
86 
91 
101 
91 
106 
101 
 
62 
 
101 
96 
91 
101 
62 
86 
 
53.84 
40 
19 
29 
52 
29 
65 
52 
 
1 
 
52 
40 
29 
52 
1 
19 
 
0.5 
84 
84 
84 
123 
91 
76 
83 
 
90 
 
88 
98 
98 
80 
80 
- 
 
90.1 
16 
16 
16 
92 
29 
7 
14 
 
27 
 
23 
45 
45 
11 
11 
- 
 
27 
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Table 8: Distribution of general quotient scores among patients with abnormal hearing 
tests 
 
Patient General quotient* 
Unilateral mild 6 months  12 months  
1 
2 
3 
4 
5 
6 
7 
Unilateral moderate 
8 
Bilateral mild 
9 
10 
11 
12 
13 
14 
Bilateral profound 
15 
101.2 
100 
99.6 
111.6 
105.8 
103.8 
106.6 
 
90.4 
 
113.4 
106.6 
102 
106.8 
76.4 
97.2 
 
47.59 
Average 
Average 
Average 
High average 
Average 
Average 
Average 
 
Average 
 
High average 
Average 
Average 
Average 
Low 
Average 
 
Very low 
78.8 
95.6 
89.9 
107.4 
93.6 
90 
83.4 
 
93.4 
 
84 
100.8 
98.6 
97.2 
81.6 
- 
 
75.64 
Low average 
Average 
Low average 
Average 
Average 
Average 
Low average 
 
Average 
 
Low average 
Average 
Average 
Average 
Low 
- 
 
low 
* Ref.4 
 
Table 9: Distribution of general quotient in the Griffiths scale among babies 
 
Griffiths scale General quotient 
 6 months 12 months 
< 70, abnormal 
71-75, borderline 
76-89, below average 
90-110, average 
111-119, above average 
> 120 
Total 
8 (0.1%) 
7 (0.9%) 
51 (6.7%) 
518 (68.4%) 
147 (19.4%) 
26 (3.4%) 
757 
18 (2.4%) 
12 (1.6%) 
224 (29.8%) 
487 (64.8%) 
10 (1.3%) 
0 
751* 
* Six babies were lost to follow-up. 
 
 
Discussion  
 
Community hearing screening in a population-based study is an ideal methodology 
to determine the efficiency of a screening program. Data gathered, as well as 
logistics and other resources can be identified, which are valuable in formulating 
the work plan. It is hoped that this undertaking will be a prelude to our efforts to 
establish a national primary care newborn hearing screening program.  
Our results showing bilateral profound hearing loss of 1 per 724 babies in a 
general population are still slightly higher than the usual 1 per 1000 proportional 
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rate often reported. It is interesting to note that even with active case identification, 
where the staff go house-to-house, in spite of the acceptable coverage rate, there 
are still a number of babies that were screened after 6 months. The value of 
universal hearing screening has been demonstrated in a recent report6 of an 8-
year follow-up of a controlled trial on universal newborn hearing screening which 
increased the proportion of all true cases of permanent childhood hearing 
impairment referred before the age of 6 months. Identification and referrals to an 
audiology unit have been improved. In addition, the value of parental education 
and awareness is emphasized and must be taken into consideration in 
establishing a community-based universal hearing screening program. Continuing 
the study to involve more parents and children would be ideal and will yield more 
information for our purpose.  
In the general population, it is expected that the prevalence rate would be lower 
compared to the hospital or specialized care units, where sick babies are referred 
and have co-morbid conditions. In this setting, monitoring the mental development 
through the Griffiths Mental Development Scale (which is an accepted assessment 
instrument of the mental development of babies up to 2 years old) and correlating 
with hearing assessments would be interesting. We have seen that in our baby 
with a bilateral profound hearing loss (ABR thresholds of 100 dB HL) the mental 
development scores (total general quotient) and in all subscales (locomotor, 
personal social, hearing and speech, eye-hand coordination, and performance) 
are lower than the average. Among those with mild hearing loss, whether 
unilateral or bilateral, at least 40% exhibit lower than average mental development. 
Whether the lower than average mental development is a result of the hearing 
impairment remains to be seen with subsequent tests and continuous assessment 
of these infants. Using the hearing and speech scale, values from this group of 
patients show that most have lower percentile scores even among those with 
unilateral mild hearing loss. This implies that while it is important to prioritize 
bilateral severe hearing losses, we may be underestimating the adverse effect of 
mild hearing loss among babies in terms of mental development.7  Assessment at 
24 months is therefore desired.  
Referrals of these babies for rehabilitation may still prove beneficial in the long-
term outcome.  
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Conclusion  
 
There seems to be a good correlation between newborn hearing screening 
outcomes and developmental outcomes, especially for babies with hearing 
impairment. Comparison of these outcomes of babies which had early 
identification and rehabilitation, even among babies with mild hearing losses, will 
provide evidence to support the practice of rehabilitating such children as early as 
possible.  
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Abstract 
 
Objective: 
To explore effects of pesticide exposure on the auditory system, specifically on 
hearing status based on auditory brainstem responses.  
 
Methods:  
A cohort of pregnant women was identified in several communities in a rural area 
from April 2002 to February 2003 and followed up until delivery. Mother-infant 
dyads were assessed for exposure to pesticides. Maternal  and fetal exposures to 
environmental toxic products were determined by measuring levels in maternal 
hair and blood, and infant cord blood, hair, and meconium respectively. Hearing 
status was measured using otoacoustic emissions (OAE) and confirmed by 
diagnostic auditory brainstem responses (ABR) measured at 80, 60, and 40 
decibels.Waves I, III, V were identified and absolute latencies measured, including 
inter-peak latencies from waves I-III, I-V, and III-V. Pesticide exposure was then 
correlated with latencies of Waves I, III, V, and interpeak latencies of waves I-III, I-
V, and III-V. Hearing loss and pesticide exposures were correlated with Griffiths 
Mental Development Scores (GMDS). 
 
Results: 
Significant delays in the ABR wave latencies were noted in the group with 
exposure to pesticides. Propoxur was the most common toxic product detected in 
infants and meconium the best substrate for its detection. There was a 1.4% risk 
of hearing loss with exposure to propoxur (RR=0.52 (0.12-2.30), p = 0.06), a 
6.25% risk with cypermethrin exposure (RR= 4.53 (0.61-33.64), p = 0.10) and 
6.25% risk with pretilachlor exposure (3.13 (0.44-22.30), p = 0.07). Griffith’s  Mental  
Developmental Scale scores (GMDS-hearing and speech subscale and general 
quotient scores) were not significantly different between exposed and unexposed 
groups. However, three infants with positive exposures and hearing loss had 
below average, or low to average scores using this scale. 
 
Conclusion: 
 Maternal exposure to environmental toxic products may affect the auditory 
pathway in infants at birth. Pregnant women should limit their exposure to such 
toxic products in order to avoid neurodevelopmental effects particularly on hearing 
because this is very important  in the critical stage of  language and speech 
development. 
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Introduction 
 
In a tropical primarily agricultural country like the Philippines, environmental toxic 
products such as pesticides and insecticides abound in most homes given 
previous reports of high prevalence of infestations with pests such as flies(97.7%), 
roaches (89.8%) and mosquitoes (97.6%).1 Use of these products is deemed 
justified when the significant prevalence of pests and vector-borne diseases is 
considered, whether in the farm or at home. The acute toxic effects of these 
products seen in acute poisoning have already been identified, and include effects 
on the central nervous system manifesting as varied neurological symptoms and 
behavioral changes.2 Profound bilateral sensorineural hearing loss has been 
associated with peripheral neuropathy in the extremities following acute poisoning 
from combined mixture of 75% malathion and 15% metamidophos.3 
The auditory pathway has also not been spared from neurotoxin effects of other 
substances such as lead4,5, 6 cocaine7, and methylmercury8, as established with 
delayed brainstem auditory evoked potentials. Combined exposure to 
organophosphates and pyrethroid insecticides revealed an associated high 
frequency hearing loss in 57% of exposed Brazilian farm workers.9 Central 
auditory dysfunction assessed through pitch pattern sequence and duration 
pattern sequence showed 56% of exposed workers with central hearing disorder 
and a relative risk of 7.58 for the group exposed to insecticides (95% CI 2.9-19.8) 
when compared to the non-exposed group.10 
In the rural areas where numerous chemicals are released in the environment it 
would be sensible to assess the possibility that such exposures can also affect the 
auditory system. Constant use of these products results in sub-clinical exposure of 
humans  albeit in much lower concentrations insufficient enough to cause acute 
toxic effects. Chronic sub-clinical effects seem difficult to assess considering the 
intricate measurement of use and subsequent exposure. Despite this, it is 
important to determine the presence of such products in a community, 
demonstrate exposure to such products, and identify possible short- and long term 
effects. This would help in regulating and possibly modifying behaviors regarding 
use of such products especially in pregnant women who may unduly increase the  
risks to the fetus with their exposure. 
Previous studies1,8 have shown that appropriate assessment of exposure may be 
performed through analysis of various biological matrices, of which maternal hair 
was found to be the most robust for detecting maternal exposure to pesticides  
and meconium found to be the most sensitive for establishing exposure in 
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infants.1,8 These studies found propoxur to be the most common toxic product 
found in meconium in about 23.8 %. 
Correlation of neuro-development determined through GMDS and hearing status 
by screening with OAE and ABR showed good correlation between the presence 
of hearing loss and developmental delay.11 This study looks at the possible effects 
of pesticide exposure on the infantile auditory system specifically looking at 
changes in ABR wave latency measures in those with maternal and infant 
exposures to environmental toxic products. 
 
 
Materials and methods 
 
All pregnant women consulting at the Bulacan Provincial Hospital from April 2002 
to February 2003 were identified and recruited to participate in the study. Study 
participants who did not consent and who failed to submit for follow-up were 
excluded. The study was approved by the Human Investigation Committees at 
both Wayne State University and the University of the Philippines Manila. Informed 
consent was obtained for collection of demographic information, blood and hair 
samples from the mothers and their infants, meconium samples from newborns, 
and newborn hearing screening and diagnosis using OAE with ABR testing. 
Maternal blood and hair samples were collected upon recruitment and delivery, 
while infant cord blood samples were obtained at birth, infant hair and meconium 
samples were obtained later in the nursery. To ensure sample adequacy for 
analysis, collection of samples were pursued in homes of the study participants. 
Hair was taken from the nape or base of the scalp with the size of a pencil eraser 
in diameter. Meconium was collected  from diapers during the first 2 days of life. 
Methods of collection and preparation of specimens and measurement of 
pesticides in various specimens have been extensively described in previous 
articles related to the study.1,8 Pesticides were measured in micrograms/deciliter. 
Newborns of identified pregnant mothers underwent OAE (Welch Allyn® 
Audiopath EOAE Screener 29230) and ABR (Interacoustics EP15) testing and 
assessment of mental development by developmental pediatricians at 6, 12 and 
24 months using the GMDS – locomotor, personal-social, hearing and speech, 
hand and eye coordination, and performance tests.11 The presence of OAEs will 
show   a   ‘pass’   result,   and   the   absence   of   OAEs   will   show   a   ‘refer’   result,  
suggesting normal and abnormal cochlear functions, respectively. ABR  recorded 
with standard machine followed American National Standards Institute (ANSI) 
standards. Determination of the presence of wave V after introducing clicks sound 
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at different loud intensities (from 100 decibels (dB) to 30 dB) was performed. 
Evaluation of the ABR tracings to determine presence of waves I, III, V and their 
inter-peak latencies (I-III, I-V, III-V) in milliseconds were performed. Infants were 
classified as having normal hearing if wave V was present at or below 40 dB 
suggesting possible normal auditory pathway, and with  hearing loss if wave V was 
present at greater than 40 dB suggesting possible abnormal auditory pathway. 
The latencies of wave I, III, V were determined to determine any delay in the 
appearance of the response, indicating possible insults in the auditory pathway. 
The samples were analyzed for commonly used pesticides: cyfluthrin, propoxur, 
chlorpyrifos, cypermethrin, pretilachlor, bioallethrin, malathion, diazinon, trans-
fluthrin, lindane and DDT. The pesticides measured included most of the major 
ingredients of different preparations of insecticides and pesticides. In the 
Philippines, there are 17 various preparations such as sprays, vaporizer, mats, 
mosquito coils, moth bag and oil spray. Maternal and infant exposures to several 
pesticides and metabolites were correlated with auditory brainstem response 
latencies to determine possible associations. 
 
 
Results 
 
There were 686 newborns (365 males (53.2%) and 321 females (46.8%)) with 
data on maternal and infant exposure to pesticides and auditory brainstem 
responses. Mean age of babies on the day of testing is 2 months (±2.63), with 
72.7% tested at 2 months. At 3 months 78.57% of all the babies could undergo 
ABR testing and 100% were tested by 12 months of age (Table 1).  
 
Table 1: Distribution  of  newborns’  age  when  ABR  was  performed  (N=686). 
 
Age in months Frequency % 
1-3 
4-6 
7-9 
10-12 
 539 
 50 
 89 
 8 
 78.57 
 7.29 
 12.97 
 1.17 
Total  686  100.00 
Mean : 2.41 months ± 2.63; 
Range 11 months, 1-12 
50th percentile at 1 month 
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Table 2: Laterality of newborns with Wave V threshold >40 dB (with hearing loss) (n=15). 
 
Laterality Frequency % 
Bilateral 
Unilateral 
 Right 
 Left 
 7 
  
 4 
 4 
 46.66 
  
 26.67 
 26.67 
Total  15  100.00 
 
Table 3: Overall mean auditory brainstem response latencies, right and left ears. 
 
80 dB 
Parameters Right Left p 
Absolute wave 
Latencies 
I 
III 
V 
1.50 (±0.30) 
4.23 (±0.33) 
6.47 (±0.40) 
1.49 (±0.29) 
4.23 (±0.35) 
6.47 (±0.41) 
0.19 
0.67 
0.65 
Interpeak wave 
Latencies 
I-III 
III-V 
I-V 
2.73 (±0.30) 
2.25 (±0.25) 
4.98 (±0.41) 
2.76 (±0.30) 
2.24 (±0.25) 
4.99 (±0.41) 
0.04 
0.64 
0.14 
60 dB 
Parameters Right Left p 
Absolute wave 
Latencies 
I 
III 
V 
2.21 (±0.43) 
4.80 (±0.48) 
6.92 (±0.47) 
2.19 (±0.43) 
4.80 (±0.48) 
6.92 (±0.49) 
0.08 
0.31 
0.98 
Interpeak wave 
Latencies 
I-III 
III-V 
I-V 
2.58 (±0.37) 
2.13 (±0.28) 
4.70 (±0.51) 
2.61 (±0.36) 
2.10 (±0.24) 
4.69 (±0.50) 
0.49 
0.36 
0.60 
40 dB 
Parameters Right Left p 
Absolute wave 
Latencies 
I 
III 
V 
2.93 (±0.42) 
5.38 (±0.41) 
7.53 (±0.49) 
2.84 (±0.48) 
5.42 (±0.45) 
7.53 (±0.61) 
0.42 
0.002 
0.42 
Interpeak wave 
Latencies 
I-III 
III-V 
I-V 
2.41 (±0.36) 
2.14 (±0.28) 
4.48 (±0.46) 
2.54 (±0.35) 
2.13 (±0.32) 
4.60 (±0.47) 
0.00 
0.70 
0.12 
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Fifteen infants were noted to have significant hearing loss , with 47% bilateral and  
only the right or left ear abnormal in 53% (Table 2). As shown in Table 3, the 
subjects had no differences in latency measures between the left and right sides 
for all the stimulation intensities utilized except for delay in IPL I-III on the left at 80 
db stimulation, and wave III and IPL I-III significantly delayed in the left after 40 db 
stimulation. At 60 db, no differences were noted between the right and left ears. It 
was considered important to look at latency measures separately for the right and 
left to detect evidence of  right and left differences and if present report these 
separately for comparison to those with notable hearing loss. As detailed in Table 
4, there were nine pesticides with positive exposures measured in meconium, the 
best matrix for infant exposure with  levels of propoxur, diazinon, malathion, 
bioallethrin, pretilachlor, DDT, cyfluthrin, cypermethrin, and DDE. The highest 
frequency of exposure was noted for propoxur at 21.2 % (165/777) of the infants. 
 
Table 4: Frequency distribution of infants with positive maternal and infant environmental 
exposure to various pesticides 
 
Pesticides Maternal Hair (%) Infant Hair (%) Meconium (%) 
Lead 25.8 9.9 0 
Cadmium 0.2 9.9 0 
Mercury 24.7 9.9 0 
Arsenic 7.5 17.7 0 
Malathion 0.9 0 0.3 
Chlorpyrifos 0.1 0.1 0 
Bioallethrin 9.0 0 0.3 
Pretilachlor 0.1 0 0.8 
DDT 0.2 0 0.5 
Propoxur 9.9 0.3 21.2 
Diazinon 0 0 0.1 
Cyfluthrin 0 0 0.8 
Cypermethrin 0 0 1.5 
DDE 0 0 0.2 
 
For maternal hair which is the best matrix for maternal exposure, there were ten 
pesticides with positive exposure  includinglead, mercury, arsenic, cadmium, 
propoxur, malathion, chlorpyrifos, bioallethrin, pretilachlor, and DDT.  However, 
evidence of exposure  to only six  pesticides  such as  arsenic, lead, cadmium, 
mercury, propoxur and chlorpyrifos were noted in infant hair.  
Table 5 shows the ABR wave latency measures in infants with hearing loss  
defined as ABR wave V thresholds greater than 40 dB compared with those 
without hearing loss ( < 40 dB  ABR wave V threshold). This serves as a good 
reference for the next table that examines effects on ABR latencies following infant 
exposure to propoxur.  
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Table 5: Comparison of latencies of ABR parameters between infants with hearing loss  
(Wave  V  threshold  >  40  dB)  and  without  hearing  loss  (Wave  V  Threshold≤  40  dB). 
 
80 dB Right Left 
 (> 40 dB) (≤  40  dB) p (> 40 dB) (≤  40  dB) p 
Parameters (n=11) (n=677)  (n=11) (n=677)  
Absolute wave 
Latencies 
I 
III 
V 
1.79 (±0.52) 
4.38 (±0.50) 
6.53 (±0.60) 
1.50 (±0.29) 
4.22 (±0.32) 
6.47 (±0.40) 
.00 
.02 
.10 
2.02 (±0.53) 
4.48 (±0.60) 
6.67(±0.71) 
1.48 (±0.27) 
4.23 (±0.34) 
6.47 (±0.40) 
.00 
.00 
.00 
Interpeak wave 
Latencies 
I-III 
III-V 
I-V 
2.58(±0.31) 
2.15 (±0.24) 
4.74 (±0.49) 
2.73 (±0.30) 
2.25 (±0.25) 
4.66 (±0.35) 
.54 
.91 
.27 
2.46 (±0.22) 
2.20 (±0.22) 
4.98 (±0.41) 
2.76 (±0.30) 
2.24 (±0.25) 
5.00 (±0.40) 
.18 
.85 
.23 
60 dB Right Left 
 (> 40 dB) (≤  40  dB) p (> 40 dB) (≤  40  dB) p 
Parameters (n=6) (n=677)  (n=11) (n=677)  
Absolute wave 
Latencies 
I 
III 
V 
2.23 (±0.37) 
4.89 (±0.46) 
6.91 (±0.69) 
2.21 (±0.44) 
4.80 (±0.38) 
6.47 (±0.40) 
.50 
.33 
.06 
2.56 (±0.54) 
5.06 (±0.63) 
7.09 (±0.86) 
2.18 (±0.43) 
4.80 (±0.48) 
6.91 (±0.49) 
.27 
.08 
.00 
Interpeak wave 
Latencies 
I-III 
III-V 
I-V 
2.61 (±0.34) 
2.02 (±0.29) 
4.50 (±0.50) 
2.58 (±0.37) 
2.13 (±0.28) 
4.70 (±0.51) 
.73 
.61 
.94 
2.44 (±0.20) 
2.03 (±0.33) 
4.51 (±0.45) 
2.61 (±0.36) 
2.10 (±0.24) 
4.70 (±0.50) 
.06 
.12 
.78 
40 dB Right Left 
 (> 40 dB) (≤  40  dB) p (> 40 dB) (≤  40  dB) p 
Parameters (n=11) (n=677)  (n=11) (n=677)  
Absolute wave 
Latencies 
I 
III 
V 
2.87 (±0.14) 
5.33 (±0.47) 
7.44 (±0.70) 
2.93 (±0.42) 
5.38 (±0.41) 
7.53 (±0.49)  
.35 
.45 
.03 
2.81 (±0.36) 
5.33 (±0.40) 
7.57 (±0.73) 
2.84 (±0.49) 
5.42 (±0.45) 
7.53 (±0.61) 
.77 
.78 
.34 
Interpeak wave 
Latencies 
I-III 
III-V 
I-V 
2.73(±0.42) 
2.11 (±0.51) 
4.76 (±0.52) 
2.40 (±0.35) 
2.14 (±0.28) 
4.48 (±0.46) 
.94 
.11 
.95 
2.56 (±0.01) 
2.09 (±0.33) 
4.70 (±0.49) 
2.54 (±0.35) 
2.13 (±0.32) 
4.59 (±0.47) 
.06 
.47 
.81 
 
 
The differences in latencies (Wave I, III, V) and interpeak latencies (IPLs I-III, I-V, 
III-V) in auditory brainstem responses between infants exposed (with positive 
pesticide exposure, maternal hair and meconium) and infants unexposed (with 
negative pesticide exposure, maternal hair and meconium) to  propoxur are shown 
in Table 6. With propoxur exposure(as detected in meconium among infants)  ABR 
testing at 80 db showed significant differences in the latency of wave III and IPL I-
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III on the right, wave III, V and IPL I-III both on the left ears. No major differences 
were seen at 60dB and 40dB. 
 
 
Table 6: Comparison of absolute wave latencies and interpeak wave latencies between  
infants with and without meconium exposure to environmental pesticide propoxur. 
 
80 dB   
Latencies Right Left 
 Exposed Unexposed p Exposed Unexposed p 
I 
III 
V 
1.50±.27 
4.16±.31 
6.43±.40 
1.51±.31 
4.25±.33 
6.49±.40 
.75 
.006 
.13 
1.48±.27 
4.18±.35 
6.42±.44 
1.49±.30 
4.25±.34 
6.49±.40 
.75 
.03 
.08 
Interpeak wave 
Latencies 
I-III 
III-V 
I-V 
2.66±.30 
2.27±.24 
4.93±.43 
2.75±.30 
2.24±.25 
4.99±.41 
.002 
.24 
.19 
2.70±.31 
2.25±.27 
4.94±.44 
2.77±.30 
2.24±.25 
5.00±.40 
.02 
.86 
.11 
60 dB   
Latencies Right Left 
 Exposed Unexposed p Exposed Unexposed p 
I 
III 
V 
2.17±.40 
4.79±.36 
6.93±.45 
2.22±.45 
4.86±.39 
6.92±.48 
.35 
.58 
.77 
2.17±.35 
4.78±.49 
6.94±.49 
2.19±.46 
4.80±.49 
6.92±.50 
.69 
.63 
.66 
IPL 
I-III 
III-V 
I-V 
2.60±.38 
2.15±.23 
4.74±.49 
2.58±.36 
2.12±.29 
4.70±.52 
.71 
.29 
.49 
2.60±.36 
2.13±.26 
4.70±.47 
2.62±.36 
2.10±.24 
4.69±.5 
.66 
.12 
.86 
40 dB   
Latencies Right Left 
 Exposed Unexposed p Exposed Unexposed p 
I 
III 
V 
2.90±.4 
5.39±.4 
7.54±.4 
22.93±.43 
15.38±.42 
97.52±.50 
.68 
.70 
.67 
2.93±.47 
5.46±.43 
7.58±.56 
2.81±.49 
5.41±.46 
7.52±.64 
.11 
.27 
.32 
IPL 
I-III 
III-V 
I-V 
2.41±.39 
2.16±.22 
4.52±.52 
2.41±.35 
2.14±.30 
4.47±.44 
.99 
.47 
.49 
2.49±.39 
2.11±.23 
4.59±.48 
2.56±.34 
2.13±.35 
4.60±.47 
.25 
.37 
.90 
 
 
There were differences found sporadically in different waves and pesticides.  In 
some cases exposure to certain pesticides was found in 1 or 2 infants only, yet 
effects could be more pronounced as in diazinon, found in meconium of only one 
infant with abnormal ABR wave V threshold greater than 80 db suggestive of 
severe to profound hearing impairment.  
Correlating exposures to pesticides and  hearing loss (Tables 7-9), 2 infants had 
exposure to propoxur, with a 1.4% risk of hearing loss, lower compared to the 
2.7% risk of hearing loss in infants without exposure. On the other hand, 1 infant 
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exposed to cypermethrin had hearing loss, with a 6.25% risk, higher compared to 
the unexposed group of 1.34%. Remarkably, this infant had propoxur exposure as 
well. One infant had pretilachlor exposure and a mild unilateral hearing loss with a 
6.25% risk compared to the unexposed group with 1.99% . 
However, there were no significant differences noted between the exposed and 
unexposed groups with regards to GMDS-hearing and speech subscale and 
general quotient scores. 
 
Table 7:  Association of propoxur exposure with status of hearing (ABR threshold) 
 
 Presence of wave V at 
Propoxur >40dB <40dB Total 
 (+) 
 (-) 
2 
14 
141 
411 
143 
525 
Total 16 652 668 
Riskexposed  =2/143        (1.4%) 
Riskunexposed  =14/525 (2.7%) 
Relative risk  =0.52 (0.12-2/30)  P=0.0565 
1St Infant:  Wave V at 80dB at the right (1.6ug/L) 
2nd Infant: Wave at 100dB both ears (0.32ug/L) 
 
Table 8:  Association of cypermethrin exposure with status of  hearing (ABR threshold) 
 
 Presence of wave V at 
Cypermethrinexp >40dB <40dB Total 
 (+) 
 (-) 
1 
9 
15 
643 
16 
652 
Total 10 658 668 
Riskexposed  =1/16  (6.25%) 
Riskunexposed  =9/643  (1.34%) 
Relative risk  =4.53 (0.61-33.64) P=0.1019 
1st Infant: Wave V at 80dB at the right (2.82ug/L) 
 
Table 9.  Association of  Pretilachlor exposure with status of hearing (ABR threshold) 
 
 Presence of wave V at 
Pretilachlor >40dB <40dB Total 
 (+) 
 (-) 
1 
13 
15 
639 
16 
652 
Total 14 644 668 
Riskexposed  =1/16  (6.25%) 
Riskunexposed  =13/652 (1.99%) 
Relative risk  =3.13 (0.44-22.30) P=0.0723 
3rd Infant: Wave V at 50dB at the left (0.48ug/L) 
 
Scrutinizing the 3 infants with exposures and hearing loss, there were low scores  
in GMDS scoring noted. In infant 1 with 2 exposures at unilateral moderate 
hearing loss, performance scores were low, although the general quotient scores 
were average at 6 and 12 months (Table 10). Infant 2 had propoxur exposure and 
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bilateral profound hearing loss, with below average scores (Table 11). Infant 3 had 
pretilachlor exposure and unilateral mild hearing loss, showing modest scores in 
hearing & speech and performance with average general quotient scores (Table 
12). 
 
Table 10: Griffith’s  Mental  Development  Scale  of  Infant  1 
Infant 1 – positive exposure for propoxur&cypermethrin with moderate hearing loss 
 
Scores SQ %tile SQ %tile 
 6 mo 6  Mo 12 mo12 MO 
Hearing/language 
Performance 
109 
62 
71 
1 
98 
90 
45 
27 
General quotient 90.4 (average) 93.4 (average) 
 
 
Table 11: Griffith’s  Mental  Development  Scale  of  Infant  2 
Infant 2 – positive for exposure to propoxur with bilateral profound hearing loss 
 
Scores SQ %tile SQ %tile 
 6 mo 6  Mo 12 mo12 MO 
Hearing/language 
Performance 
42.3 
53.84 
0.5 
0.5 
68.6 
90.1 
2 
27 
General quotient 47.6 (below average) 75.6 (below average) 
 
 
Table 12: Griffith’s  Mental  Development  Scale  of  Infant  3. 
Infant 3 – positive exposure to pretilachlor with mild unilateral hearing loss 
 
Scores SQ %tile SQ %tile 
 6 mo 6  Mo 12 mo12 MO 
Hearing/language 
Performance 
100 
106 
50 
65 
86 
76 
19 
7 
General quotient 103.8 (average) 90 (average) 
 
 
Discussion 
 
While measures of central auditory effects among workers exposed to 
organophosphates have been reported, this study looks at early auditory effects in 
newborns with maternal exposure to environmental products. Propoxur, 
cypermethrin and pretilachlor exposure may contribute to increased risk of hearing 
loss given possible effects on the fetus or newborns. Three (3/668, 0.45%) with 
positive exposure to environmental toxins had wave V thresholds >40 dB, 2 of 
which  at  ≥80dB,  and  1/668  (0.15%)  with  multiple  exposures  had  wave  V  threshold 
≥80dB.   
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The risk of hearing loss with exposure to identified substances appears clinically 
significant whether these are subtle changes found in ABR wave latencies or wave 
V threshold elevations. The GMDS scores show good correlation at least among 
infants with hearing loss and documented exposures to toxins. 
In this cohort, despite the rarity of the condition, there seems to be an association 
between exposure to propoxur, cypermethrin, and pretilachlor and hearing loss. It 
is important to delineate the effects of these exposures and eliminate other causes 
for the hearing loss. Further analysis using multivariate regression may be 
employed to include all possible variables that may contribute to hearing loss, so 
that individual effects may be quantified.  
This study, along with published studies on OAE & ABRs from our center 
encouraged us to push for legislation to institute newborn hearing screening so 
that  even in far-flung areas these babies can benefit from early identification and 
intervention for prevention of deleterious effects on neuro-development which 
include speech and hearing. The present study would be helpful in educating 
people in the community on the proper use of commonly available pesticides, in 
addition to motivating health regulatory bodies to further investigate effects, 
institute regulations in pesticide use, and conduct regular monitoring of burden of 
exposures. 
 
 
Conclusion 
 
Maternal exposure to some pesticides may contribute to an increased risk for 
hearing loss among infants in an agricultural community. Further monitoring of 
infants may be helpful to assess if these effects are reversible or permanent.  
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Abstract 
 
Objective:  
To undertake a cost analysis of screening, diagnostic and intervention strategies 
for bilateral permanent hearing loss with modeling performed to compare the 
projected costs of three newborn hearing screening options: passive, targeted and 
universal. 
 
Method:  
Both short-term and long-term costs for hearing screening centers and for families 
of hearing impaired children are projected based on calculations of the cost of 
hearing screening given local published prevalence of congenital hearing loss and 
the effectiveness of testing strategies.  
 
Results:  
Using published data on the prevalence of hearing loss and experience from a 
pilot universal newborn hearing screening project at a national tertiary hospital 
(Philippine General Hospital) benefits and savings from UNHS on a national scale 
greatly outweigh the immediate costs of testing and intervention. 
 
Conclusion:   
A universal newborn hearing programme will accrue more savings compared to a 
no screening or selective screening strategy when implemented even in a 
developing country like the Philippines. There is a need to emphasize increased 
awareness among professionals and parents, an efficient follow-up of cases and 
early hearing and speech rehabilitation for this UNHS to be truly cost beneficial 
both from an individual and societal perspective.  
 
 
Introduction 
 
Congenital hearing impairment which is bilateral profound or permanent congenital 
hearing loss (PCHL) occurs in 1.3 per 1000 Filipino newborns.1 This rate is at par 
with rates of congenital hearing impairment worldwide.2 Milder forms or unilateral 
hearing loss may also be associated with developmental delays thus increased 
surveillance is needed.1 Early detection of hearing impairment is the key to early 
intervention which in turn may avoid the deleterious effects on psychosocial, 
linguistic, educational aspects of development.3 Thus it is important that babies 
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with hearing impairment be identified by age 6 months, so that early intervention 
can be given and they can develop mentally as their normal hearing peers.4 While 
there may be countries where age at intervention may not be correlated with 
linguistic advantages  this may be due to cultural differences in how young 
children are treated in terms of language development.5 Ruben (2000) 
emphasized the high cost of hearing loss to society which in the U.S. comprised 
about 2.5% of the GDP.6 Other studies that compared targeted screening versus 
universal newborn hearing screening showed the latter to be more cost effective 
given the high cost of educating a hearing impaired child. Targeted screening 
seems to be more attractive in terms of less cost for testing compared to universal 
newborn hearing screening. However, when overall costs for intervention and 
education are considered for those whose hearing loss are diagnosed late, 
universal newborn hearing screening proves to be more cost effective.7,8 This 
study describes a developing country perspective on the cost of universal newborn 
hearing screening versus a targeted or selective newborn hearing screening 
strategy.  
 
 
Methods 
 
Short-term and long-term costs for hearing screening centers and for families of 
hearing impaired children are projected as well as societal costs. Calculations 
included cost of hearing screening given local published prevalence of congenital 
hearing loss and the effectiveness of testing strategies. It should be pointed out in 
the Philippines most of the costs for hearing screening, diagnosis and intervention 
are borne by individual patients or their families as third party payers do not pay 
for such services except for cochlear implantation which is a surgical procedure 
covered by the Philippine Health Insurance Corporation. Cost of hearing aids nor 
cochlear implant devices as well as speech therapy and auditory training are 
likewise not covered.  
 
Newborn Hearing Screening Options 
In many cases there are three options for detection of hearing impairment in 
newborns: no screening or passive detection; early screening for high-risk babies 
only or targeted or selective newborn hearing screening (TNHS or SNHS); or early 
screening for all babies or universal newborn hearing screening (UNHS).  
The first option of passive detection will obviously result in delay in detection, with 
age at diagnosis of hearing impairment usually by 2 to 3 years old. A retrospective 
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analysis by Canale and co-workers reported the mean age of identification of 
severe to profound hearing loss who were not screened at 29 months of age.9 In 
this scenario, the intervention, whether by hearing aids or surgery, is then 
expected to be also delayed.  
The second option tests only those who are high-risk based on existence of the 
following factors10 as described by JCIH (2007) shown in Table 1.  
 
Table 1: 2007 JCIH Criteria for High Risk of Congenital Hearing Loss  
 
 caregiver concern regarding hearing, speech, language or developmental delay; 
 family history of permanent childhood hearing loss; 
 neonatal intensive care of more than 5 days or any of the following regardless of 
length of stay: extracorporeal membrane oxygenation or ECMO [which is similar to a 
heart-lung machine], assisted ventilation, exposure to ototoxic medications [or drugs 
that are toxic to the ear such as] (gentamicin and tobramycin) or loop diuretics 
(furosemide/Lasix) and hyperbilirubinemia [jaundice] that requires exchange 
transfusion [replacement of blood or plasma]; 
 in utero [prenatal and maternal] infections, such as cytomegalovirus, herpes, rubella, 
syphilis, and toxoplasmosis;  
 craniofacial anomalies [deformities], including those that involve the pinna, ear 
canal, ear tags, ear pits, and temporal bone anomalies 
 physical findings such as white forelock, that are associated with a syndrome known 
to include a sensorineural or permanent conductive hearing loss; 
 syndromes associated with hearing loss or progressive or late-onset hearing loss, 
such as neurofibromatosis, osteopetrosis, and Usher syndrome; other frequently 
identified syndromes include Waardenburg, Alport, Pendred, and Jervell and Lange-
Nielsen; 
 neurodegenerative disorders, such as Hunter syndrome, or sensory motor 
neuropathies, such as Friedrich ataxia and Charcot-Marie-Tooth syndrome; 
 culture-positive postnatal infections associated with sensorineural hearing loss, 
including confirmed bacterial and viral (especially herpes viruses and varicella) 
meningitis; 
 head trauma, especially basal skull/temporal bone fracture that requires 
hospitalization; chemotherapy. 
 
 
This second strategy of selective or high-risk screening, although more 
economical in terms of number of babies to test, may not be cost-effective due to 
the high number of false-negatives (or wrongly labeled as normal when child is 
hearing impaired) based on risk factor history alone. Also it usually misses those 
children who may be hearing impaired but do not exhibit any risk factors. Studies 
have shown the proportion of such children may even be higher than those with 
risk factors and have hearing impairment.11 The Wessex Universal Neonatal 
Screening Trial Group diagnosed those with permanent childhood hearing loss 
who had risk factors such as stay in the NICU or low birth weight, infections in only 
about 8% giving support to the need for objective screening to be applied 
universally to newborns.12 Another study showed that the proportion of children 
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without risk factors may even be higher than those who are high-risk and have 
hearing impairment, with as much as 78% of newborns who fail hearing screening 
as having no risk factors.13 A study by Olusanya highlighted the operational 
constraints that will limit its effectiveness and  the limited evidence with respect to 
the validity of high risk factors especially in resource poor countries where such 
TNHS have been recommended.14 
 
The third strategy, UNHS, is more comprehensive since it tests all babies, and 
ideally should catch all newborns with hearing impairment, whether high-risk or 
not. However in the real setting, while 29% of the NICU babies at the Philippine 
General Hospital had a bilateral refer rate the follow-up rates for second testing 
may be low, with as much as 73% of patients who require second testing lost to 
follow-up15,16 in a related study done at the Philippine General Hospital NICU. Also 
the screening test has a false-positive rate of 13.6% and false-negative rate 
(labeled as normal when actually hearing-impaired) of 0.6%.1 It should be noted 
that the false-positive rate may mean additional testing which are unnecessary 
since the child is not hearing-impaired, while a low false-negative rate implies that 
only a small proportion of babies who are truly hearing-impaired are mislabeled. 
Previous studies in the United States have been done in order to assess the cost-
effectiveness of UNHS vs. high-risk screening only. The estimated cost of 
detection per child who is hearing-impaired was $ 4,609 for UNHS vs. $ 8,239-
9,920 for TNHS.17 In a later study, it was shown that, the total cost of detection in 
case of no screening was $ 69,000; TNHS resulted in incremental savings of 
$16,400 per  infant while UNHS yielded an incremental savings of $ 44,300 per 
infant whose deafness was diagnosed by age 6 months.8 Similarly in Germany 
selective newborn hearing screening would at first seem economical but when the 
number of missed diagnosis and the consequent delay in language development 
and the other interventions are factored in, UNHS proves to be more cost 
effective.7 In Brazil where prevalence of sensorineural hearing loss was 0.96:1000, 
the cost of hearing screening was US$ 7.00 and the annual cost of universal 
newborn hearing screening program was US$ 26,940.47.18 
 
Projected Costs for Screening Centers 
Initial costs for screening centers would be capital-intensive due to equipment 
acquisition. For most, an otoacoustic emissions (OAE) or automated auditory 
brainstem response equipment will constitute the required machines in a Newborn 
Hearing Screening center. The OAE test takes only a few minutes to test in a 
quietly resting baby though the AABR requires a slightly longer duration for testing. 
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In most Philippine hospitals OAE is used as an initial test. For those who fail the 
initial OAE screening, a second OAE test is recommended, preferably within one 
month of the first test. For those who fail both OAE tests, confirmation either by 
ABR or ASSR is recommended. OAE has good concordance with ABR among 
Filipino neonates19 thus its utility as a screening tool has a proven track record. An 
OAE machine may cost P230,000 (Exchange rate of 1 USD = PhP40), while an 
AABR averages  P700,000. An ABR and  ASSR machine  can cost 800,000 to 
1800000 pesos respectively. These machines are durable and can last more than 
ten years with very little maintenance costs though may need calibration on an 
annual basis. Automated ABR has been recommended abroad as more practical 
for initial screening due to its lower false-positive rate and better cost-effectiveness 
as compared to OAE.16 However we have no current data as to its sensitivity and 
specificity as a screening tool among Filipinos and on-going studies have just 
started. Although initial capital layout for equipment seems large, the actual cost 
becomes cheaper as more babies are screened over years of use, because the 
costing is reflected as the initial capital plus operating expenses divided by the 
total number of newborns screened. Operating expenses would likely constitute 
salaries of technicians and disposable supplies. In Manila, the standard salary for 
one technician would be P8000/month. Disposable supplies include batteries, 
alcohol, cotton, office supplies, etc. which may total at least P1000/month. Given 
that the initial capital and operating expenses will be the standard price for at least 
five years, the total cost for a screening center may then be at least 2,138,000 
pesos.  
 
Modeling using the pilot results form the Philippine General Hospital 
From October to December 2007, a single technician was able to screen 995 
babies or 75% of all newborns at the Philippine General Hospital or PGH (Table 
2).  
Of   those  screened,  10.5%  had  a   “refer”   result   and   thus   required  a  second  OAE  
test to confirm hearing impairment. However, of 104 babies only 27% followed up. 
Of those who followed up, only one child was confirmed by OAE to have a hearing 
impairment. This may mean that we could have missed another 2-3 hearing-
impaired children who failed the first OAE test but did not come back for a second 
test. If these numbers are projected to a 5-year period, a single technician should 
be able to screen 23,886 babies, (at 90% screening rate) plus at least 2507 
children for a second OAE test (at 10.5% refer rate). Once the program is 
entrenched, there is a tendency to improve coverage due to greater public 
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awareness and improved testing mechanisms to a 95% screening rate and 4% 
refer rate with about 80% follow-up  or  “recall”  rate. 
  
Table 2: Pilot OAE Screening of Babies at the Philippine General Hospital, October-
December 2007 
 
Total No. of  Babies Born in one quarter+ 1,327 
Number of Babies Screened in one quarter 995 
Rate (Actual) Screening 75% (995/1,327) 
Total Rate of Screening in 5 years 90% (1,194 babies) 
Ideal Rate of Screening after 5 years 95% (1,261 babies) 
Initial Refer Rate obtained 10.6% (104 babies) 
Ideal Refer Rate 4% (48 babies or 4% of 1,194) 
Follow-up or Recall Rate obtained 27% (104/995) 
Ideal Follow up Rate 80% (80% of 48 babies or 38) 
 
 
If we were to use the data above as basis for capital (i.e. without costing for place 
of testing/rent/bills, etc.) and number of hearing-impaired children detected over 5 
years, the cost of detecting a hearing-impaired child on second OAE screening is 
at least P63,000 (Table 3).  
 
Table 3: Cost Calculations based on Projections of Baseline Data from the Philippine 
General Hospital 
 
Total babies born in one quarter =1327 
At 90% (Ideal Rate) of 1327  = 1,194 
Projected for 1 year           = 1,194 x 4 quarters /year = 4,777 
Projected for 5 years       = 23,886( 4777 x 5 years ) 
With 4% Refer Rate          = 955 
80% Follow Rate for Initial  
Refer Patients = 764 
Total Number of babies Tested for 5 years = 24,650 (P87 per OAE test) 
 (80% Follow-up Rate) 
Total Number of Babies Tested for 5 years  
 With 100% Follow-up  = 24,841 (P86 per OAE test) 
Based on Prevalence of PCHL = 34 babies with PCHL in 5 years 
Average cost per HI child P62,882 
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If follow-up testing will have improved rates, that is at 100%, the cost of early 
detection may go down to P58000 per hearing-impaired child. 
 
The usual cost for OAE in testing centers is currently P300, while the ABR or 
ASSR test varies from P800 to P2,000. Based on the computations above, the 
actual cost (without inflation) for screening a large volume over five years, if 
packaged at 2 OAE tests plus 1 ABR test, may amount to only P87 per child. 
 
Projected Costs for Individuals  
The impact of the previous calculation becomes more obvious if we were to 
compare the costs at an individual level. The change in expected impact and cost 
happens at two levels: (1) early detection, i.e. by age 3 months; and (2) early 
intervention, i.e. by age 6 months. If a child who is hearing-impaired is not 
screened by age 3 months, chances are high that the hearing impairment will be 
detected much later, usually at age 2-3 years, when the parent already sees the 
speech and language development to be much delayed compared to other 
children. If no intervention is done, then the lost opportunity to go to mainstream 
schools or the requirement for special education has a high price tag, which easily 
reaches hundreds of thousands of pesos over a period of 10 years. This has a 
snowball effect, which results in difficulty in acquiring a job in adulthood or 
underemployment, not just because of speech and language impairment but also 
poorer mental development compared with hearing individuals, and also less 
socialization capabilities and probably emotional problems from isolation and 
depression. We can arbitrarily assign a value of P30,000 per year for special 
education for 10 years, and lost income of P100,000 per year for 40 years, for a 
total of P4.3 million over a lifetime. Please note however that this is a very 
conservative estimate with no additional costing for inflation. If a child is diagnosed 
to have hearing impairment by  age 6 months but intervention is not given early 
enough, then we can assume that the cost is similar to the previous scenario, plus 
the additional cost of testing. There are also cases in which intervention is given at 
later than 1 year and some improvement in speech and language is seen, 
however their development is still not at par with hearing children.4 There will be a 
late diagnosis by age 2-3 years and special education services will be needed for 
a longer period of time. Compared to the previous estimate this will be higher 
because of additional costs from additional intervention. 
If a child is diagnosed to have hearing impairment by age 6 months and 
intervention is given immediately, then the chance of developing normal speech 
and language development is much higher and may be expected to be near 
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normal if the hearing impairment is mild to moderate. Currently one hearing aid 
may range between P10,000 to P100,000 depending on the model. If we take the 
average cost of P30,000 - P45,000 for one ear, then those requiring hearing aids 
for both ears would require about P60,000 - P90,000 for optimal development. For 
those with moderate to severe hearing impairment lifetime use of hearing aids will 
be expected along with intensive speech rehabilitation and special education 
services. If we assume that replacement of the unit is required every 5-10 years, 
then the cost for hearing aids alone over a 60-year period would amount to at least 
P240,000-720,000 (plus batteries). Compared to the scenario with no intervention, 
this translates to a lifetime savings at the individual level of about P3.3 to 4 million. 
In some cases of severe to profound hearing loss, instead of hearing aids, 
cochlear implantation is required. Cochlear implantation involves the surgical 
insertion of an electrode into the inner ear of a severe-to-profoundly deaf child so 
that through electrical stimulation the neural cells can conduct impulses to the 
brain and hearing  restored. The rate for the entire treatment now runs at about 
P1.2 million. Since the technology is still new (only 15 years in the Philippines), it 
is hard to say how many times a cochlear implantee would need re-implantation, 
and most patients would probably prefer no additional surgery. If we assume that a 
re-implant is required, perhaps due to technological advances or wear-and-tear, 
but will be done only after 30 years, then the cost would double over a 60-year 
period, which would amount to savings of P1.9 million. However only 60% of the 
children can be mainstreamed and 40% will still need special education services 
for at least five years to 10 years. Thus If we also assume that no re-implantation 
is required, then the savings would be higher at P3.1 million less the cost of 
special education (P30,000 x 10 years or P300,000) or about P2.8 million pesos. 
The prospect for employment for the deaf child is less than a normal hearing child 
but if implanted at an early age with sufficient language development will be better 
than for those who are deaf without any speech development at all. Thus at the 
individual level, a simple diagnostic exam with a basic cost of P87 can actually 
save an individual or family millions of pesos if done at the newborn period! 
 
Projected Costs for National Program 
If we try to imagine the costs and savings of the previous calculations on a 
national scale, then we have to take into account the prevalence of congenital 
hearing impairment in the country and the sensitivity and specificity of OAE as a 
screening test. Studies have shown the cost effectiveness of a screening 
intervention to be largely dependent not only on the cost per patient but also the 
baseline prevalence (Risk) of hearing impairment.21 As previously reported, the 
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prevalence of bilateral profound hearing impairment among Filipino newborns is 1 
in 724, or 0.14%.1 If we include those with unilateral and mild-to-moderate hearing 
loss, the prevalence is 16/724 or 2.2%. However those with unilateral or milder 
forms of hearing loss may not necessarily require intervention. Still they may be 
diagnosed using the OAE as a screening test, thus we use the higher prevalence 
estimate in our succeeding estimation. In the same report, the sensitivity or 
chance of detecting a truly hearing-impaired child using OAE (as compared to the 
gold standard, ABR) is 86.4%, while the specificity or chance of detecting a 
hearing child as normal is 99.4%. 
Following the method of Gorga and Neely22, to estimate the cost-savings of a 
screening program, the posterior probabilities of each test result has to be 
computed, as follows: 
 P00 = P(normal) x P(pass|normal) = 0.98 x 0.99 = 0.97 
 P11 = P(impaired) x P(fail|impaired) = 0.02 x 0.86= 0.019 
 P01 = P(normal) x P(fail|normal) = 0.97x 0.006 = 0.006 
 P10 = P(impaired) x P(pass|impaired) = 0.02 x 0.136 = 0.003 
The immediate cost for the first two outcomes that is normal+pass(C00) and 
impaired+pass(C10) is equal to the screening test, which we may assign as P200. 
This is because after the test, no other intervention is expected. For a normal-fail 
result, the cost (C01) includes unnecessary testing with ABR, which when added to 
the screening OAE test, amounts to P2,000 (50 US dollars) The cost of 
impaired+fail result is negative because of savings from early detection of hearing 
impairment, since we prevent delayed language and speech. We can assign this 
value (C11) as -P4.3 million. With these assumed probabilities and costs, we can 
compute the expected cost of the test per baby: 
  Expected Cost  = C00 x P00 + C11 x P11 + C01 x P01 + C10 x P10 
    = P300 x 0.97 – P4,300,000 x 0.019 
+ P2000 x 0.006 + P300 x 0.003= -P82,000  
Since the result has a negative value, this means that in the long-term the OAE 
screening test exceeds immediate costs when probabilities of each test outcome is 
applied. The value is the expected cost each time the screening test is 
administered. If about 1.8 million Filipinos are born yearly, then the benefit of 
performing a hearing screening test on every baby would be about P147.2 billion. 
This shows that the projected savings over 60 years or over the long term greatly 
exceeds the immediate cost of performing UNHS. Also if we compare the cost of 
testing each baby born in a year (i.e. P300 x 1,800,000 = P540,000,000) versus 
the total savings amortized on a yearly basis  (i.e. P147,239,000,000 / 60 = 
P2,453,988,630), then it can be easily shown that the newborn screening program 
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would be cost-effective even on the first year of national implementation. On the 
other hand the cost of UNHS will likely lead to other health interventions to be 
displaced such that further examination of this cost and incorporation into existing 
health promotion and primary and secondary prevention programmes will need to 
be seriously considered. 
 
 
Discussion  
 
A review of literature has shown that risk factor screening alone while seemingly 
attractive in terms of cost  for a developing country with scarce resources likely will 
entail more loss both from an individual and societal perspective considering the 
high cost of delayed intervention with hearing amplification, special education and 
speech rehabilitation. From this study both the projected costs that took into 
consideration the local prevalence of bilateral permanent hearing loss and the 
effectiveness of OAE as an objective hearing screening test showed significant 
cost benefit. The main problem, however, is the lack of awareness among 
Filipinos, even among physicians, of the need to refer newborns for hearing 
screening.23 Even if a public hospital like the Philippine General Hospital is utilized 
as a model savings can still be obtained despite a less than ideal follow up or 
recall rate. The age of referral of only 30% at less than one year of age previously 
reported will likely improve.1 Increased awareness among parents, health 
professsionals with an efficient testing and high recall rate will result in the 
substantial savings calculated in this study. For the initial implementation of the 
UNHS in the Philippines all the main islands of Luzon, Visayas and Mindanao 
should have screening diagnostic and intervention centers strategically placed in 
the first year. Within two years an additional 14 centers will need to be added such 
that all 17 regional hospitals in the country will be fully equipped to accept  infants 
who have failed an initial hearing screen. The challenges of implementing a UNHS 
in the Philippines seem daunting but given the advantages to the family and the 
hearing impaired individual himself and society in general the implementation on a 
national scale may prove to be a worthwhile undertaking indeed. 
 
 
Conclusion 
 
Universal newborn hearing screening is a cost-effective strategy that should merit 
support from government as a program for promotion of hearing health among 
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Filipinos. Our estimates clearly show the huge financial benefits from the 
individual, family and societal perspectives that could be reaped from such a 
program if the required support services are provided, both with early detection 
and early intervention measures. Notwithstanding the cost of UNHS, further 
examination with respect to implications on funding of existing programs and as 
implemented in other developing countries with incorporation into the existing 
programmes for maternal and child health and newborn care such as that of using 
the immunization platform will still need serious consideration. The current 
projections in cost have been made possible through the availability of local data 
on prevalence and effectiveness of testing strategies. Based on pilot studies, cost 
benefit will be assured if good follow-up can be maintained for those who fail the 
initial OAE screen and if low false-positive rates can be achieved by technicians, 
which underscores the importance of increased public awareness, training of 
health practicioners, and timely interventions.  
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Abstract 
 
Objectives:  
To determine the prevalence of gap junction beta-2 (GJB2) or connexin 26 (CX26) 
variants in Filipino cochlear implantees, and to describe radiologic findings, 
audiologic results and auditory performance after cochlear implantation (CI). 
 
Methods:  
Thirty cochlear implantees with unknown etiology for congenital severe-to-
profound hearing loss and 30 controls provided venous blood samples for study. 
Radiologic evidence of temporal bone abnormalities, residual hearing status and 
post-CI auditory performance are described. Statistical analysis was performed for 
hearing thresholds before and after CI and for Parent Evaluation of Auditory/Oral 
Performance in Children (PEACH) scores based on the presence of cochlea-
vestibular anomalies, age at CI and time since CI. Genomic DNA was extracted 
from venous blood, PCR-amplified and sequenced for GJB2 variants.  
 
Results:  
One patient was compound heterozygous (c.[35delG ];[235delC]) for GJB2 
variants. The variants p.Gly4Asp, p.Val27Ile and Val37Ile were identified in both 
patients and controls, including two implantees who were homozygous for 
p.Val27Ile and p.Val37Ile. No significant association was found between post-CI 
improvement in threshold or PEACH scores and the following variables: age at CI, 
duration of hearing aid use prior to CI, presence of cochleovestibular anomalies 
and completeness of electrode insertion. Although no significant change in 
audiometric thresholds due to time since CI was detected, PEACH scores were 
significantly improved with longer implant use at all conditions (quiet, noise and 
overall; p<0.05). 
  
Conclusions: 
The prevalence of causal GJB2 variants in Filipino cochlear implantees is low 
(3.3%). Within this population the allele frequencies of the p.Val37Ile variant in 
patients and controls is >10%, which supports a non-pathogenic role for this 
variant. The low prevalence of GJB2 variants precluded any association testing 
with CI outcome, although our results suggest better auditory outcome with longer 
CI use. Future genetic studies within the Filipino population should be able to 
control for population admixture. 
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Introduction 
 
Mutations in the gap junction beta-2 (GJB2) gene, which encodes the connexin 26 
protein that is important for potassium recycling and for hair cell depolarization/ 
repolarization, are the most common cause of congenital hearing loss of genetic 
origin in many populations.1-2 Among different ethnic groups, there is great 
variability in genotype-phenotype correlations; for example, specific variants such 
as c.35delG are more prevalent in Caucasians1, c.167delT among Ashkenazi 
Jews3 and c.235delC among Asian populations.4 In many developed countries, 
GJB2 sequencing has become routine for genetic screening in hearing-impaired 
neonates. In contrast, in developing countries like the Philippines, infections 
(rubella, labyrinthitis, meningitis) and ototoxicity comprise about 50% of the known 
causes of congenital hearing loss, while in 24% the etiology remains idiopathic.5 It 
is believed that some cases of hearing loss in the latter group may be due to 
genetic mutations, although the proportion is not as high as in developed 
countries. In this report, the GJB2 gene was sequenced in Filipino cochlear 
implantees with bilateral severe-to-profound hearing loss of unknown etiology and 
in control subjects. Radiologic abnormalities, pre-implant residual hearing and 
auditory performance are also described. Given the challenges to access cochlear 
implant services in the country, our cohort of cochlear implantees provides a 
unique opportunity to study prevalence rates for hearing impairment genes among 
Filipinos and auditory outcomes after cochlear implantation (CI). The study results 
will be useful for genetic counseling, prognostication and formulation of a national 
policy for hearing care.  
 
 
Materials and methods 
 
Patient recruitment and clinical evaluation 
The study was approved by the University of the Philippines Manila-National 
Institutes of Health Ethics Review Board prior to study initiation. Informed consent 
was obtained from adult subjects and parents of pediatric cochlear implantees. 
From an initial pool of 100 cochlear implantees, 30 cochlear implant recipients with 
bilateral severe-to-profound hearing loss of no definitive etiology from perinatal 
and maternal history, as well as 30 adult control subjects (median age 32 years, 
range 21-59), all of Filipino descent, were enrolled in the study. Otoscopic and 
audiometric screening of control subjects was performed and normal hearing 
results were obtained. For the cochlear implantees, all medical records including 
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radiologic and audiometric evaluation were reviewed. CI was performed by a 
single surgeon, and audiometric and speech evaluation was performed in one 
center. Within a soundproof setting, pure-tone thresholds for the pediatric patients 
were obtained by auditory steady-state response using a Biologic NavPro 
(Mundalein, Illinois, USA) machine. In the adult patients, audiometric evaluation 
based on the standard Hugh Westlake method was performed using a MADSEN 
Aurical Plus audiometer (Denmark). When computing the averages of the hearing 
thresholds, a default value of 120 dB was used to indicate profound hearing loss 
that is beyond the audiometer limits. In the patients with bilateral CI, thresholds for 
the better hearing ear were used. 
Auditory outcomes were rated by Categories of Auditory Performance (CAP)6 and 
Parent Evaluation of Auditory/Oral Performance in Children (PEACH) scales7. 
CAP is an index consisting of eight performance categories arranged in the order 
of increasing difficulty, with category 8 as highest performance. The parents of the 
pediatric cochlear implantees were asked to fill out a PEACH questionnaire7.  
Statistical analysis was performed for improvement in hearing thresholds and 
PEACH scores based on the presence of temporal bone anomalies, successful 
electrode insertion, duration of hearing aid use prior to CI, age at CI and time since 
CI.  Improvement in hearing thresholds was derived by subtracting averaged pre-
CI thresholds from averaged post-CI thresholds. The Mann-Whitney-Wilcoxon 
rank sum  test  for  dichotomous  independent  variables  and  Spearman’s  correlation  
test for linear independent variables were performed using R8.  
 
DNA extraction, PCR-amplification and direct sequencing 
Genomic DNA was extracted from whole blood using the Qiagen QIAamp DNA 
Blood Midi Kit (Qiagen, Valencia, Calif., USA). The coding exon (exon 2) of the 
GJB2 gene was sequenced for all participating subjects. PCR primers 5’   - 
gAAgTCTCCCTgTTCTgTCC – 3’   (forward)  and  5’   - AATCTAACAACTgggCAATg 
– 3’   (reverse) were designed with NetPrimer software (Premier Biosoft 
International, Palo Alto, Calif., USA).  
PCR was performed in 45-μL reaction mixtures, each containing 1 X PCR buffer 
(20 mM Tris-HCl, pH 8.4; 50 mM KCl), 2.5 mM MgCl2, 0.2 mM  of each deoxy-
nucleotide, 0.2 μM each of the forward and reverse primers, 3 U Taq DNA 
polymerase (Invitrogen, Carlsbad, Calif., USA) and 1.5 μL gDNA. PCR conditions 
were as follows: initial denaturation for 4 min at 94C; 38 cycles of denaturation at 
94°C for 30 s, annealing at 67.6°C for 30 s and extension at 72°C for 50 s; and a 
final extension for 10 min at 72C. Amplicons were then sequenced bidirectionally. 
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For patient samples in which only one variant in exon 2 of GJB2 was found, 
sequencing of exon 1 and adjacent intronic regions of the gene was performed. 
 
 
Results  
 
Clinical Description 
Of 30 cochlear implantees, 14 were male and 16 female. The median age at CI 
was 4 years 7 months (range 15.5 months to 27 years; average age at CI 7 years). 
Nineteen patients were implanted on the right ear, 7 in the left ear, and 4 
bilaterally. All patients were implanted with MED-EL devices, except for 1 patient 
who received a Cochlear Nucleus Freedom Contour device. 
Half of the patients had normal cochleovestibular findings by CT and/or MRI scans 
including 3 with unilateral high-riding jugular bulb. Nine patients (30%) had 
enlarged vestibular aqueducts (EVA), 1 patient had bilateral Mondini dysplasia and 
another implantee had bilateral malformed cochleae with incomplete partition. A 
child with bilaterally malformed cochleae, vestibules and semicircular canals also 
had congenitally absent cochlear and inferior vestibular nerves in the right ear. 
Three implantees showed evidence of superior semicircular canal dehiscence.  
For 3 children, only auditory brainstem response or auditory steady-state response 
results were available, which showed bilateral severe-to-profound hearing loss. 
Among 27 patients with preoperative hearing thresholds, the average across 
frequencies 0.5-4kHz was 106.6 + 12.0 dB (median 111, range 80-120). Post-
operatively the average across frequencies for aided thresholds was 38.9 + 10.4 
dB (median 38.8, range 25-80). This means an improvement in hearing of 66.7 + 
16.6 dB on average (median 71.2, range 31.8-95). Of 3 adult implantees (age >20 
years), 2 had a CAP score of 7, while 1 had a CAP score of 6. The child with 
bilateral inner ear malformations and right eighth nerve aplasia was implanted in 
the left ear and had PEACH scores of 4% for quiet, 10% for noise and 7% overall 
conditions. For 24 other children with PEACH scores, the average scores were as 
follows: quiet condition, 74.1 + 21.3% (median 81, range 21-96); noise condition, 
66.0 + 25.5% (median 67.5, range 0-100); overall condition, 70.5 + 22.6% (median 
75, range 16-98). 
The presence of temporal bone abnormalities, successful electrode insertion and 
length of pre-CI hearing aid use did not significantly influence post-CI threshold 
improvement and PEACH scores. When plotted against age at CI and time since 
CI [Figure 1], no significant relationship with post-CI improvement was found in the 
threshold. Likewise, no significant change in PEACH scores was detected based 
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on age at CI. On the other hand, PEACH scores were significantly associated with 
time since CI at all conditions (quiet, R=0.54, p<0.01; noise, p<0.05; overall, 
R=0.49, p<0.05) [Figure 1].  
 
 
 
Figure 1: Correlation plots for improvement in auditory thresholds and PEACH scores 
based on time since CI. (a) Difference between pre- and post-CI thresholds versus time 
since CI (R=0.25, NS). (b) PEACH scores in the quiet versus time since CI (R=0.54, 
p=0.005). (c) PEACH scores in the noise condition versus time since CI (R=0.42, p=0.04). 
(d) Overall PEACH scores versus time since CI (R=0.49, p=0.015). 
 
 
GJB2 Genotypes 
Of 30 cochlear implantees who were sequenced for GJB2, only 3 patients were 
homozygous or compound heterozygous for GJB2 variants [Table 1]. One 
implantee was compound heterozygous for the c.35delG and c.235delC 
mutations. A second implantee was homozygous for the p.Val37Ile variant. 
However, the p.Val37Ile variant was found in the heterozygous state at high allele 
frequencies in both patients (10%) and controls (11.7%; Table 1). One implantee 
was homozygous for p.Val27Ile, while 2 controls carried both the p.Val27Ile and 
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p.Glu114Gly variants in the heterozygous state. Previous reports have concluded 
that p.Val27Ile was a polymorphism, either as a single variant or within a 
haplotype with p.Glu114Gly.9-10. Another known variant, p.Gly4Asp11, was 
identified in the heterozygous state in both implantees and controls at allele 
frequencies of 3.3 and 5%, respectively. Sequencing of exon 1 of GJB2 in 9 
implantees who were heterozygous for a single variant in exon 2 did not detect 
additional variants.  
 
Table 1: GJB2 genotypes among Filipino cochlear implantees and control subjects 
 
GJB2 Genotype Implantees Controls 
c.[35delG ];[c.235delC] 1 0 
p.[(Val37Ile)];[(Val37Ile)] 1 0 
p.[(Val27Ile)];[(Val27Ile)] 1 0 
p.[(Val27Ile;Glu114Gly)] 0 2 
p.[Gly4Asp];[=] 2 3 
p.[Val27Ile];[=] 1 0 
p.[Val37Ile];[=] 6 7 
None 18 18 
Total 30 30 
 
 
The patient who was compound heterozygous for c.[35delG];[235delC] was partly 
of Spanish descent. Based on oral history, multiple individuals from both sides of 
the patient’s  family also have hearing impairment. His temporal bone CT revealed 
bilateral EVA (fig. 2a). Although he was implanted in the right ear at the age of 6 
years, he had been using hearing aids since he was 2 years old. He had excellent 
post-CI thresholds (average 41.2 dB; fig. 2b) and PEACH scores of 90-92% at all 
conditions. 
The implantee who was homozygous for p.Val37Ile had EVA in the left ear (fig. 2c) 
and was implanted bilaterally at the age of 4 years. His average for aided 
thresholds was 25 dB (fig. 2d) and his PEACH scores ranged from 66-70%.  
 
 
Discussion  
 
Whether the p.Val37Ile variant damages hearing function or not remains 
controversial. This variant has been associated with mild-to-moderate hearing 
impairment in multiple individuals.12. Bioinformatics analysis using Polyphen-213 
predicts the possibly damaging effect of the variant, while the SIFT14 program 
labels p.Val37Ile as tolerated. On the other hand, functional studies indicate that 
Chapter 7 
91 
 
the p.Val37Ile variant disables induction of the formation of homotypic gap junction 
channels in Xenopus oocytes and may even have a dominant negative effect.15-16 
However, the allele frequency in both patients and controls in this study is >10%, 
and thus p.Val37Ile may be considered a common variant among Filipinos. It also 
appears to be equally prevalent among hearing-impaired individuals and controls 
in East Asian populations.11,17  
 
 
Figure 2: (a-b) Temporal bone CT showing bilaterally enlarged vestibular aqueducts (EVA, 
black arrowheads) in the patient with the GJB2 c.35delG/c.235delC genotype. (c) Visual 
reinforcement audiometry (blue with multiple hash) in the same patient at the age of 5 
years showed severe hearing impairment, while aided thresholds (letter S) indicated 
hearing within the speech spectrum. Red, right ear; blue, left ear.  
(d) Thresholds further improved 3.5 years after CI in the right ear. (e) Temporal bone CT 
of the patient who is homozygous for the GJB2 p.Val37Ile variant (black arrowhead). (f) 
Unaided thresholds indicated profound hearing loss in the right ear (red circles) and 
severe hearing impairment in the left ear (blue crosses). Thresholds obtained with hearing 
aids (blue S) were within the hearing range at 500-4,000 Hz but not at 500 and 8,000 Hz. 
Implant-aided thresholds (red S) were within the speech range across all Frequencies 
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Likewise both the p.Val27Ile and p.Val37Ile variants have high allele frequencies 
in Indonesians18 and Malaysians19. Given this evidence, it is possible that the 
patient in this study was homozygous for the p.Val37Ile variant because of high 
variant allele frequencies within the population, and that the profound hearing loss 
in this patient has a different etiology. 
Because only 1 patient carried recessive GJB2 mutations in two alleles, the 
prevalence of hearing impairment due to GJB2 variants within this cohort of 
Filipino cochlear implantees is low (3.3%). The prevalence of causal variants in 
GJB2 is similarly low in other Southeast Asian countries Indonesia18 and 
Malaysia19, where the Filipino population originated historically. Since GJB2 
variants are not a common cause of hearing impairment within the Filipino 
population, GJB2 sequencing will not be cost-effectient as a genetic screening 
tool. 
Although the GJB6 gene is known to cause hearing impairment through digenic 
inheritance with GJB220, the GJB6 gene was not tested in this study. Similarly, 
only a few individuals were sequenced for exon 1. Worldwide, the prevalence 
rates for mutations within GJB2 exon 1 and GJB6 remain low, and such mutations 
are only common in individuals from select populations who have heterozygous 
mutations in GJB2.21-23  
Earlier studies suggested better post-CI outcomes in children with GJB2 
mutations24-25, but more recent studies demonstrate that such outcomes in GJB2-
positive children are mainly due to duration of CI use or younger age at 
implantation.26-27 Although the number of pediatric cochlear implantees in this 
study was small, we were able to show an improvement in PEACH scores with 
increasing time since CI, but not with age at implantation. 
Due to the low prevalence of GJB2 mutations, it was not possible to test if there is 
an association between the presence of GJB2 mutations and post-CI auditory 
outcomes. However, merely increasing the sample size may not be a cost-efficient 
strategy in conducting future genetic research. The identification of the c.35delG 
and c.235delC variants in 1 individual due to mixed ancestry may reflect 
population admixture within the general Filipino population, which is to be 
expected   from   the   country’s   migration   and   colonization   history.   This   forebodes  
difficulties in designing case-control studies for this population and can result in 
false-positive associations due to population admixture. Thus, future genetic 
studies within the Filipino population require a study design and statistical analysis 
that properly control for population admixture and substructure. 
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General Discussion 
 
Affecting at least 1.5 per 1000 live-births, congenital hearing loss remains as one 
of the most common congenital disorders in children (Parving ,1999). Given the 
pervasive individual disadvantages from psychosocial, educational and economic 
as well as the societal perpectives, efforts at early detection of childhood 
prelingual deafness should be pursued ( Ruben, 2000). Following the principles 
laid out earlier by Wilson and Junger in 1968 and Davis and co-workers in 1997 
newborn hearing screening can pose a number of challenges (Davis et al., 1997; 
Wilson and Junger,1968). Embarking on newborn hearing screening entailed the 
much needed epidemiological studies in the Philippines with the end view of 
determining the practicality and value of universal newborn hearing screening 
(UNHS). The Joint Committee on Infant Hearing (JCIH) in 1982 already 
considered the problems related to delayed diagnosis of childhood deafness and 
recommended identification by the age of 3-6 months (JCIH, 1982). A high risk 
register was then proposed since otoacoustic emissions (OAE) testing protocols 
had just been introduced (Kemp, 1978). Subsequently after about 8 years, the 
JCIH recommended the use of OAE to facilitate the early detection of hearing loss 
in newborns (JCIH, 2000; JCIH 2007).   
 
Chapters 2 and 3 highlight the earlier studies carried out at the University of the 
Philippines Manila – Philippine General Hospital on the subject of hearing 
screening in neonates and very young children. In Chapter 2 the sickest babies at 
the neonatal intensive care unit of University of the Philippines- Philippine General 
Hospital were tested using OAE and it was noted that 29% had bilateral refer 
rates. The associated risk factors were determined and low birth weight and male 
gender were found to be significant (Chiong et al., 2003). A related study showed 
that only 8% of the babies who referred were brought back for retesting and 75% 
of them eventually passed (Quintos et al., 2003). As a national university hospital, 
most pregnant women who come to this hospital have had poor perinatal care, 
with pregnancy related complications and come from the very poor socioeconomic 
strata. Another related study soon from our center identified retrospectively the 
common etiologic basis of severe to profound deafness among cochlear 
implantees and showed  maternal Rubella as the most common at 32% while 
other infections such as chronic otitis media (4%), meningitis and labyrinthitis (4%) 
and ototoxicity would cumulatively approximate 50% of the preventable causes of 
profound deafness consistent with the report of Alberti (Chiong, 2006;Chiong and 
Villanueva, 2012; Alberti, 1996).  Similarly, risk screening alone will likely miss out 
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on 42% of hearing impaired children such that the need for more objective 
screening with OAE for example will be justified (Wrightson, 2007).   
 
In Chapter 3 we report on 379 children referred to the Ear Unit of the Philippine 
General Hospital during a ten month period. These were children with notable 
delay in speech or whose pediatricians suspected the possible presence of 
hearing loss. The age of referral was more than 12 months in 63% and only 32 % 
percent between 5-12 months of age. This shows that most of the children were 
diagnosed beyond the age at which diagnosis and intervention are ideally provided 
without the deleterious consequences on speech and language development. In 
this chapter we also demonstrated good concordance of OAE and ABR. Most 
screening centers will likely be able to afford only to buy OAE equipment given the 
cost of ABR equipment in our setting. Indeed as reported by others the sensitivity 
and specificity of OAE vis-a vis the ABR as a gold standard was noted to be very 
good (Llanes & Chiong, 2004). On the other hand we also were interested in 
knowing how many of those who would have a flat ABR response might have 
some residual response with ASSR. A related study also from our center pegged 
this at 85% with the possibility of an objective way of choosing which ear gets the 
hearing aid amplification initially considering that most families could only afford to 
buy one hearing aid (Tan et al., 2009). 
 
Chapters 2 and 3 delved with testing children in an academic tertiary hospital and 
so there was still the need to determine the prevalence of hearing loss in 
newborns in the community setting. Chapter 4 showed this to be 1.38 per 1000 
livebirths (Chiong et al., 2007). This rate is similar to the reported prevalence rates 
on newborn hearing loss worldwide. If we are to consider unilateral and mild 
hearing loss the rate increases to 22 per 1000 live-births (an 18 fold increase). 
However given that the ABR testing done to confirm the level of hearing was 
performed above the age of 3 months in more than 40%, the percentage of 
children with temporary hearing loss (eg. from otitis media) could not be clearly 
ascertained.  Nevertheless,  using  the  Griffith’s  Mental  Development Scoring it was 
noted that even those with mild or unilateral hearing loss had a developmental 
delay compared to those with normal hearing during the first two years of life. 
These children have been followed for another three years and it would be 
interesting to know whether such initial delays would be overcome as the children 
grew older. A study to look at outcomes in terms of development in the longer term 
is being planned. 
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Other etiologic factors responsible for the delayed auditory development  in some 
of these children might include pesticides as most of the children tested came from 
an agricultural community where pesticides and insecticides were commonly used 
either to increase crop yields or reduce vector borne diseases. In Chapter 5, 
changes in ABR latency measures were studied among infants and correlated with 
the exposure to some of these environmental toxic products (Chiong et al., 2012). 
The matrices for determination of exposure among mother-infant dyads were 
noted to be maternal hair for exposure of mothers and meconium for infants being 
most robust (Ostrea et al., 2008; Ostrea et al., 2009). Propoxur noted to be the 
most prevalent neurotoxic product effected some changes in some latency 
measures between the exposed and non-exposed group suggesting an effect in 
the auditory system. This indeed highlights a need for increasing the awareness 
among   the   “at   risk”  population.  The  need   to   formulate  effective  strategies   in   this  
regard and the outcomes could be the subject of more studies in the future. 
Interestingly, as opposed to the initial experience in the hospital based screening 
of the NICU babies this study however showed that with community workers 
directly in touch with the mothers more than 90% of the babies could be tested 
within 9 months. Thus this community based strategy had an advantage over the 
hospital based testing. Along with the fact that only 40% -70% of births take place 
in hospital facilities in the Philippines (Philippine Fact Sheet,2010), a community 
based screening programme need to be formulated. As most of the rural areas will 
not have objective hearing screening equipment in hospitals an alternative hearing 
screening test had to be developed. Earlier screening methodologies described in 
literature such as the infant distraction test were revisited (Ewing & Ewing, 1944). 
In the UK these tests were being done at 8-9 months by a health visitor attending 
until objective testing using otoacoustic emissions tests became in widespread use 
(McCormick, 1983; McCormick, 2002). The accuracy of a human voice test 
(“BAAH”)   compared   to   OAE   was   good   and   increased   to   more   than   65%   the  
possibility of a diagnosing hearing impairment when a response was positively 
identified (Abes et al., 2012; Garcia et al., 2012). This paves the way for the 
possibility of training community health workers on both risk factors and the 
“BAAH”   test   in   places   where  OAE   equipment   are   not   available.   This   alternative  
test need not preclude objective testing as it will defeat the purpose of universal 
newborn hearing screening. However cognizant of the limited resources in some 
remote islands without these equipment and the fact that procurement of such 
may take a long time still a fifty percent chance of detecting a child who needs 
closer monitoring might still be considered valuable with increased awareness of 
the parents and caregivers tasked to monitor the babies in these areas. Otherwise, 
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where some of the babies are found to fail to respond to this initial test, health 
workers will need to refer them to the nearest locality or hospital where the service 
can be provided. 
 
Chapter 6 describes the cost analysis of a universal newborn hearing screening 
programme based on the data found in Chapters 2, 3 and 4. It was important to 
review how other countries whether developed or developing found UNHS to be 
cost effective. However as highlighted by these studies, prevalence rates and 
population at risk and the cost of services within the particular health system will 
have a lot of bearing on the eventual cost of carrying out such a programme.  
Selective or targeted hearing screening would appeal mostly to developing 
countries such as Sub-Saharan Africa and Southeast Asia (including the 
Philippines) where resources are limited and expenditure for health remain below 
the stipulated WHO rate of 5% of GDP. However as highlighted by several authors 
operational constraints would render selective screening to be not as cost-effective 
as that of a UNHS and that existing programmes within the health system of a 
country could well be utilized to cut the cost of rendering UNHS such as using 
immunization as a platform for the provision of this service ( Olunsaya, 2011). In 
Germany, when cost of education and other interventions are considered universal 
newborn hearing screening is shown to be more cost-effective (Neumann et al., 
2006). The cost analysis showed substantial savings could be obtained with the 
universal newborn hearing screening in the Philippines even during the first year of 
full implementation (Chiong et al., 2012). 
 
The results of the studies described in this thesis were used to advocate for the 
legislative mandate to carry out a universal newborn hearing screening 
programme. In 2007 the first position paper was submitted to congress and 
Senator Loren B. Legarda filed Senate Bill 2390(23) using as a basis the results of 
the studies described in Chapters 2, 3 and 4. In two years the law mandating 
Universal Newborn and Early Intervention Act of 2009 was enacted. The Newborn 
Hearing Screening Reference Center as stipulated in the IRR (Implementing Rules 
and Regulations) approved by the Department of Health in 2010  is now busy 
formulating the protocols, registry, training and laboratory proficiency 
methodologies needed to carry out the mandate(Appendix 1) (Department of 
Health, 2010).   
 
Indeed the early detection of childhood deafness is expected to lead to early 
intervention. These two tasks could be formidable in a setting where geographic 
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(the country has 7100 islands), infrastructure, low awareness regarding deafness 
prevention, lack of manpower aggravated by migration of professionals (Cheng et 
al., 2002) and cost issues of screening, diagnosis and treatment seem 
insurmountable. Nevertheless technological advances in hearing rehabilitation 
have come our shores and shown a glimmer of hope for some of these children. 
Thus it is hoped that with early detection of hearing loss more will benefit from 
early intervention and  better choices for parents and families would be made 
available.  
 
Corollary to this, genetic screening for early detection of hearing loss and its 
etiologic basis has been introduced in some countries. GJB2 or connexin 26 
mutation is the  most common cause of non-syndromic sensorineural hearing loss. 
GJB2 variants were studied among Filipino cochlear implantees (CI) and showed 
the prevalence at 3.3% mutation rate. This was not as high as that reported in 
other countries (Chiong et al., 2012) and the GJB2 variants noted can be 
explained on the basis of racial admixture in the context of Philippine colonial 
history. The prevalence of causal variants in GJB2 is similarly low in other 
Southeast Asian countries such as Indonesia ( Snoeckx et al., 2005) and Malaysia 
(Zainal et al., 2012) from which historically the main population of the Philippines 
originated. It also highlights the fact that genetic screening as espoused in other 
countries may not be that significant for the early diagnosis of hearing loss in 
childhood. Additionally, no effect of GJB2 mutation on the performance with 
cochlear implantation (CI) based on PEACH scoring (Ching & Hill, 2007) was 
noted. Other mutations such as SLC26A4 are now under investigation and another 
ongoing study looking at the identification of genes responsible for chronic otitis 
media are just some of the studies that have been formulated in order to possibly 
determine and look at the causes of early onset hearing loss among the most 
vulnerable segment of a growing population in our country where about 2 million 
babies are born each year.  
 
This thesis summarizes the work done in our institution for the last ten years which 
started with epidemiologic studies on hearing impairment among neonates and 
young children, the age of identification, some of the risk factors and common 
etiologic causes and correlation of the hearing impairment with developmental 
milestones. We investigated the ability of OAE, ABR and ASSR to diagnose these 
children in our setting. We also studied alternative behavioural hearing screening 
testing that could be utilized in areas where no such objective audiologic testing 
could be carried out. The auditory effects of maternal exposure to environmental 
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toxins during pregnancy was likewise investigated with respect to ABR wave 
latency changes following maternal and fetal exposure as measured in several 
matrices with both maternal hair and meconium as most robust for the mother-
infant dyads. Lastly the cost analysis of UNHS was investigated based on 
evidence on local prevalence data and cost of diagnostic and intervention services 
within the current health system. Initial studies on genetic basis for congenital 
hearing loss showed that GJB2 mutations accounted for only 3.3% of those with 
severe to profound hearing loss undergoing cochlear implantation with no impact 
on auditory performance with cochlear implantation. In contrast to other developed 
countries, this puts into question the importance of genetic screening in our 
setting. 
A developing country perspective on the early detection of childhood deafness is 
provided and how research evidence can be utilized successfully for developing 
national policy and legislation to address this important health issue is 
demonstrated. A manual of operations is now being finalized in preparation for full 
implementation on a national scale (CONHSCA,2012) by year 2013. 
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Summary 
 
The importance of early detection, diagnosis and intervention for congenital 
hearing loss is well supported by the fact that it is one of the most common 
congenital disorders  and is known to lead to deleterious effects with impact on the 
individual's overall psychosocial, educational and speech and language 
development. Given that established principles for hearing loss screening in 
newborns and infants are well justified, some developed countries have been able 
to mandate universal newborn hearing screening (UNHS) since the early 90's. In 
the case of developing countries it has been contended that risk factor and 
targeted or selective newborn hearing screening methods would be more practical 
with less cost. However as proven by numerous studies this strategy will miss out 
on about 50% of those with significant hearing impairment. The Philippines is in 
the medium development category ranking 112th of 187 countries on the basis of 
the human development index as of 2010. As in most developing countries 
primary prevention takes precedence over secondary or tertiary prevention 
measures given the limited resources for health care. Its growing population will 
likely magnify further the effects and toll on the economy of missed opportunities 
to ameliorate the lifelong and significant effects of congenital hearing loss. 
Universal newborn hearing screening as espoused in most reports could provide 
mitigation  but  adoption of the models in most developed countries will likely not 
be applicable given that the Philippines is an archipelago of 7100 islands and 40-
70% of births are home born and not hospital based. This thesis provides a 
developing country  framework and a systematic approach to how a universal 
newborn hearing screening programme could be operationalized given the 
foregoing realities including a burgeoning population growth with 1.8 million babies 
born on an annual basis. 
 
The second chapter of this thesis highlights the pragmatic approach of first looking 
at the sickest babies in a tertiary academic center neonatal intensive care unit and 
the proportion of babies who would fail a distortion product OAE test. There was 
note of a 29% "refer" rate with low birth weight and male gender as the most 
significant risk factors. The greatest challenge was how to have the babies return 
for a follow up confirmatory test as only 8% could be recalled for a retest of whom 
75% eventually passed. The third chapter looked at the agreement between OAE 
and ABR testing. A fairly good concordance could be established between the two. 
Additionally this study showed that referral for diagnosis of congenital hearing loss 
was delayed in the majority of cases. With only about 30% being referred at age 
Summary 
 
108 
 
below one year of age data showed hearing loss diagnosis is beyond the six 
months ideal age of intervention compatible with age appropriate speech and 
language development. This is further supported by the fact that EHDI (Early 
Hearing Detection and Intervention) programmes from the U.S. for example will 
mandate that NHS( newborn hearing screening) be done within 48 hours before 
hospital discharge  will miss out on the majority as most of the babies in the 
country especially in the rural araes are home born. However for a UNHS 
programme to be developed it was important to establish local prevalence of 
bilateral permanent congenital hearing loss. The Philippines remains to be a 
predominantly agricultural country as the study detailed in Chapter 4 that reports a 
community based prevalence of 1.4 per 1000 livebirths with bilateral permanent 
congenital hearing loss proved to be within the reported prevalence from other 
countries. The impact on early development within the first two years of life of 
various degrees of hearing loss and even unilateral hearing loss was also noted to 
be significant based on the Griffith's Mental Development Scale. Chapter five 
looked at the effects of maternal and fetal exposure to environmental toxic 
products on the ABR wave latencies highlighting the hazards of pesticides and 
insecticides on overall auditory development. The effect of exposure on latency 
changes on ABR was measured in robust matrices such as maternal hair for 
mothers and meconium for the infants. There was a significant difference found 
between the exposed and non-exposed groups using these several matrices as an 
index of maternal and infant exposure to pesticides that although already banned 
in Europe still remain commercially available in the Philippines. Propoxur was 
determined to be the most prevalent toxin in this cohort of mother-infant dyads.  
 
In Chapter six the cost analysis of a universal NHS in the Philippines was 
undertaken in order to establish the feasibility of this hearing health programme 
using the findings on local prevalence of hearing loss seen in Chapter three and 
the costs of equipment, personnel salaries and other expenses relative to the loss 
of income and educational cost of speech and aural rehabilitation. It was noted 
that there would be substantial savings that could accrue from a universal NHS 
programme even in a country like the Philippines.  
 
There were four related studies done at our center that may be considered as 
supporting the findings of this thesis. One is the study by Quintos et al. (2003) that 
reported only 8% recall rate for those who failed initial OAE testing in the neonatal 
intensive care unit in our center. This highlights the difficulty of ensuring a follow-
up study with patients hailing from afar as the referral base of patients in our 
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center is in fact national. Perhaps a community based approach will be more 
effective as also supported by Chapter 4 where more than 90% of infants could be 
examined within nine months of birth where community health workers could 
provide encouragement to the mothers to bring their babies for testing. With 
respect to confirmatory tests with ABR(auditory brainstem response) following an 
OAE  ”refer”   result  another  study  by  Tan  et  al.   (2009)  reported  that  85%  of  those  
with flat ABR had residual responses seen on ASSR (auditory steady state 
response) test. This highlights the potential value of a more comprehensive 
frequency specific and more robust electrophysiologic method of determining 
residual hearing in those with flat ABR findings which may be important where cost 
issues could delay provision for binaural hearing amplification (still an out of 
pocket expense). The third study by Garcia et al. (2011) provides a framework for 
the use of the voice test (BAAH) as an alternative test along with questionnaire 
risk factor screening for use in places where such OAE, ABR and ASSR 
equipment are still not available so that more than half of the babies with 
significant hearing impairment can still be identified. Lastly the study on GJB2 
among Filipino cochlear implantees (Chiong et al., 2013) that showed a low 3.3% 
prevalence of this mutation among profoundly deaf subjects with unknown etiology 
for deafness may be interpreted as likely putting into question the practicability of a 
genetic screening in the Philippines even as this is now espoused in other 
developed countries having high prevalence of GJB2 mutations as the cause of 
congenital hearing loss.  
 
This thesis documents the need for a systematic approach for building up the 
evidence from a developing country perspective on the value of early detection of 
hearing loss in children, the need for developing the UNHS  as a potential method 
for facilitating the early diagnosis of childhood deafness as a way of ensuring that 
early intervention can be instituted and how this may be facilitated  even with the 
operational constraints  of lack of equipment and audiologic professionals for 
example. The findings of Chapters 3 to 5 served as a basis for a law that 
mandated universal newborn hearing screening in the country that will be 
introduced in phases for the next 5-10 years.  
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Samenvatting 
 
Het belang van een vroege opsporing, diagnose en behandeling van een 
aangeboren doofheid wordt nog versterkt, omdat het om een van de meest 
frequente aangeboren ziekten gaat. Evenzo omdat een onbehandelde 
aangeboren slechthorendheid/doofheid zo een schadelijk effect heeft op de 
persoonlijke taal- en spraakontwikkeling en daarmee op de persoonlijke 
psychosociale ontwikkeling van een persoon. Nadat het belang van de screening 
bij neonaten en kinderen vanwege gehoorverlies voldoende was aangetoond, 
werd de neonatale/vroegkinderlijke gehoorscreening sinds het begin van de 
negentiger jaren in de afgelopen eeuw al in sommige ontwikkelde en 
geïndustrialiseerde landen als een verplichte routine screening ingevoerd. 
In de ontwikkelingslanden is er om praktische redenen voor gekozen om alleen en 
dan  pas gericht op het bestaan van een gehoorverlies te screenen wanneer er 
sprake is van een verhoogd risico op de aanwezigheid van een slechthorendheid/ 
doofheid. In talrijke studies is echter aangetoond dat met een dergelijke beperkte 
screeningsopzet zo een 50% van de kinderen met een ernstig gehoorverlies 
gemist wordt. De Filippijnen valt op grond van de ontwikkelingsstandaard (Human 
development category and index) in de middencategorie van landen met een 
plaats tussen nummer 112-187. Op grond van de beperkte budgetten beschikbaar 
voor gezondheidszorg heeft, evenals in de ontwikkelde landen, primaire preventie 
in de gezondheidszorg een hogere prioriteit in verhouding tot de secundaire en 
tertiaire zorg. Door toepassing van een zo beperkt screeningsprogramma 
vanwege vroegkinderlijke slechthorendheid/ doofheid zal het aantal gemiste 
gevallen van een vroegtijdige opsporing door een te verwachten bevolkings-
toename nog verder gaan toenemen. Door deze gemiste kansen om zo in 
individuele gevallen de negatieve effecten van vroegkinderlijke slechthorendheid/ 
doofheid op iemand zijn persoonlijke ontwikkeling te helpen verlichten, zullen de 
totale kosten voor de economie op landelijk niveau gaan toenemen. Een 
verschuiving van gezondheidszorgbudgetten naar de primaire preventieve 
gezondheidszorg wordt beoogd. Een algehele invoering van een bevolkings-
onderzoek op neonatale gehoorscreening in de Filippijnen zal nog op praktische 
problemen in de uitvoering stuiten, omdat de Filippijnen uit een archipel van 7100 
eilanden bestaat en omdat 40-70% van de bevallingen thuisbevallingen zijn. 
 
Dit proefschrift handelt over hoe in een ontwikkelingsland, zoals de Filippijnen, 
systematisch een bevolkingsonderzoek op neonatale gehoorscreening zou 
kunnen worden ingevoerd, weliswaar rekening houdend met de al genoemde 
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logistieke beperkingen bij een groeiende bevolking met thans al 1.8 miljoen nieuw 
geborenen/jaar. 
 
Het tweede hoofdstuk van dit proefschrift richt zich eerst op een praktische 
aanpak   door   allereerst   de   zieke   baby’s   in   een   tertiair   universitair   neonatale  
intensieve care unit op hun gehoor te onderzoeken en door zo na te gaan welke 
baby’s   falen  bij  de  oto-akoestische emissie (OAE) test. Bij 29% van hen was dit 
het geval. De belangrijkste risico verhogende factoren waren een laag geboorte-
gewicht en het mannelijk geslacht. Het bleek buitengewoon problematisch om 
deze kinderen met een negatieve OAE-test opnieuw te kunnen zien voor een 
vervolgtest op hun gehoor. Slechts 8% uit die groep bleek opnieuw getest te 
kunnen worden en driekwart van hen had vervolgens alsnog een goede uitslag. 
 
Het derde hoofdstuk gaat over de mate van gelijkwaardigheid tussen de 
otoacoustische emissie (OAE) test en Auditory Brainstem Response (ABR) test. 
Een redelijk goede overeenkomst werd tussen beide testmethoden gevonden. 
Tegelijkertijd toonde deze studie aan dat de meerderheid van de dove/slecht-
horende kinderen te laat verwezen werden voor deze diagnostiek. Slechts 30% 
van deze kinderen bleek verwezen te zijn voor het eerste levensjaar. Dit terwijl de 
leeftijd van 6 maanden de gewenste ideale leeftijd voor diagnose is om een 
passende spraak- en taalontwikkeling te kunnen bereiken. Het programma voor 
bevolkingsonderzoek om vroegkinderlijke doofheid/slechthorendheid (Early 
Hearing Detection and Intervention=EHDI) in de Verenigde Staten op te sporen 
kent als voorschrift dat het gehooronderzoek bij de neonaat (NHS=Newborn 
Hearing Screening) binnen 48 uur na de geboorte en in ieder geval voor ontslag 
uit het ziekenhuis verricht is. In de Filippijnen daarentegen - in het bijzonder in de 
landelijke gebieden -  hebben de meeste bevallingen thuis plaats. 
Voor het ontwikkelen en opzetten van het neonatale gehoorscreeningsprogramma 
in de Filippijnen was het nodig eerst de prevalentie van een beiderzijds 
voorkomend gehoorverlies te leren kennen. Landbouw is in de Filippijnen de 
belangrijkste economische activiteit. In hoofdstuk 4 wordt aangetoond dat de 
prevalentie van een beiderzijds voorkomend blijvend gehoorverlies 1.4 op de 1000 
levend geborenen is, wat valt binnen de voor andere landen gemelde prevalenties. 
Gehoorverliezen, zowel dubbelzijdige als enkelzijdige, die na de geboorte en wel 
in de eerste twee levensjaren ontstaan, blijken   volgens   de   Griffith’s   Mental  
Development Maatstaf van groot belang te zijn. 
In hoofdstuk 5 werden aan de hand van auditieve hersenstam responsies (ABR) 
de effecten van de maternale en foetale expositie aan in de omgeving 
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voorkomende schadelijke stoffen bestudeerd. Dit om de nadruk te leggen op de 
gevaren van deze pesticiden en insecticiden op de ontwikkeling van het auditieve 
systeem. Deze toxische stoffen werden gemeten in het hoofdhaar van de moeder 
en de meconium van de neonaten. Er bleek een significant verschil te bestaan 
tussen de aan deze toxische stoffen geëxposeerde en de niet daaraan 
geëxposeerde groepen personen, wat als index werd gebruikt om de expositie aan 
deze toxische stoffen uit te drukken. Het is opmerkelijk dat het gebruik van deze 
toxische stoffen in Europa al is uitgebannen, terwijl deze insecticiden en pesticiden 
op commerciële basis in de Filippijnen nog beschikbaar zijn. Propoxur bleek het 
meest voorkomende toxische stof in dit cohort van moeder-kind koppels. 
 
In hoofdstuk 6 wordt een kosten-batenanalyse opgesteld voor het algemene 
bevolkingsonderzoek op neonatale gehoorscreening (NHS) in de Filippijnen om de 
haalbaarheid van dit bevolkingsonderzoek in financiële zin te achterhalen. De in 
hoofdstuk 3 gevonden prevalentie van dubbelzijdige aangeboren slechthorend-
heid/doofheid werden hierbij als grondslag gebruikt. Als kosten werden geteld de 
kosten van de materiële testuitvoering, de salariële kosten en de overige kosten 
als gevolg van een verlies aan eigen inkomsten en de hoge kosten van revalidatie 
vanwege de spraak- en gehoorontwikkeling. Geconcludeerd werd dat aanzienlijke 
besparingen – ook in de Filippijnen – zullen resteren wanneer een algemeen 
bevolkingsonderzoek vanwege neonatale gehoorscreening zal worden opgestart. 
 
In ons universitaire centrum in Manilla werden nog 4 andere dan de in dit 
proefschrift opgenomen originele studies verricht. Een van deze vier studies is de 
publicatie van Quintos et al. (2003), die meldt dat slechts 8% van de neonaten die 
eerder onvoldoende resultaat  behaalden bij een OAE-test - uitgevoerd in een 
centrum voor neonatale intensive care - opnieuw voor vervolgtesten verschenen. 
Aangezien het geografische verwijzingsgebied voor dit neonatale intensive care 
centrum het geheel van de Filippijnen beslaat, benadrukt deze bevinding nog eens 
hoe moeilijk het is bij zo een specifieke geografische gegevenheid om een follow-
up in deze gehoorscreening zeker te stellen. 
Mogelijk zal een algemeen bevolkingsonderzoek in zijn regionale opzet hier 
effectiever blijken. De in hoofdstuk 4 vermelde bevindingen suggereren dit omdat 
in die studie 90% van de kinderen jonger dan 9 maanden oud op hun gehoor 
onderzocht kon worden. Regionale medewerkers in de gezondheidszorg wisten 
toen de moeders te enthousiasmeren om hun baby’s   op   hun   gehoor   te   laten  
testen. 
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In een andere van deze vier bijdragen ditmaal van Tan et al. (2009) worden de 
uitkomsten van de ABR (Auditory Brainstem Response) na een eerdere negatieve 
uitslag bij Otoacoustische Emissie test besproken. Bij 85% van hen met een 
vlakke curve bij hersenstamaudiometrie (ABR) werden toch nog enige responsies 
gevonden bij de ASSR (Auditory Steady State Response) test. Dit benadrukt nog 
eens de potentiële waarde van een dergelijke meer frequentie specifieke en 
robuuste electrophysiologische testmethode om alsnog restgehoor aan te tonen 
wanneer de ABR geen gehoorresten meer weet aan te tonen. Immers omwille van 
onkosten (voor eigen rekening) zou anders  in dergelijke gevallen een vroege 
dubbelzijdige hoortoestelaanpassing bij de jonge baby te lang uitgesteld kunnen 
worden met als later gevolg weer onnodig andere hoge kosten voor gehoor-
revalidatie. 
 
De derde van deze vier studies van Garcia et al. (2011) verschaft een kader voor 
het gebruik van de stemtest (BAAH) als een alternatieve test te gebruiken in 
combinatie met de risicofactoren - vragenlijst om op geografische afgelegen 
plaatsen te gebruiken in geval de andere methoden van OAE, ABR en ASSR niet 
beschikbaar zijn. Op die manier kunnen zo dan tenminste nog meer dan de helft 
van de vroegkinderlijke slechthorende/dove kinderen vroegtijdig opgespoord 
worden. 
 
Tenslotte, de vierde van deze vier publicaties, ditmaal van Chiong et al (2013) 
toont dat slechts 3.3% van de in de Filippijnen met een cochleair implantaat 
gerevalideerde kinderen met een onbekende oorzaak voor hun vroegkinderlijke 
doofheid een pathogene mutatie voor GJB2 heeft. Dit roept voor dit moment voor 
de Filippijnen de vraag op of een genetische screening voor GJB2 (DFNB1) in de 
Filippijnen wel zinvol is, als de prevalentie van deze oorzaak voor vroegkinderlijke 
slechthorendheid/doofheid in de Filippijnen werkelijk zo laag is. Voor andere 
ontwikkelde landen blijkt een dergelijke incidentie als verklaring voor het 
gehoorverlies (DFNB1) veel hoger (20-50%) te zijn. 
 
Dit proefschrift toont het nut om door een systematische aanpak evidentie te 
verschaffen om ook in ontwikkelingslanden vroegtijdig vroegkinderlijke slecht-
horendheid/doofheid te willen opsporen. Evenzo wordt aangetoond dat een 
algemeen bevolkingsonderzoek voor neonatale gehoorscreening een goede 
mogelijkheid is om vroegtijdig vroegkinderlijke slechthorendheid/doofheid op te 
sporen om aldus een vroege interventie ter revalidatie va het gehoor te 
bewerkstelligen. Dit kan dus zelfs al ten dele lukken bij gebrek aan de benodigde 
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technische audiologische infrastructuur en bij gebrek aan audiologisch geschoolde 
professionals. 
 
De in hoofdstuk 3 en hoofdstuk 5 beschreven bevindingen vormen de basis voor 
het tot stand brengen van een wet in de Filippijnen, die het landelijk opstarten van 
een bevolkingsonderzoek voor neonatale gehoorscreening regelt en wel binnen 
een periode te tellen vanaf nu 5-10 jaar. 
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